Review

The Mediterranean Diet and Cardiovascular Health
A Critical Review

Miguel A. Martínez-González, Alfredo Gea, Miguel Ruiz-Canela

Abstract: **The Mediterranean diet (MedDiet), abundant in minimally processed plant-based foods, rich in monounsaturated fat from olive oil, but lower in saturated fat, meats, and dairy products, seems an ideal nutritional model for cardiovascular health. Methodological aspects of Mediterranean intervention trials, limitations in the quality of some meta-analyses, and other issues may have raised recent controversies. It remains unclear whether such limitations are important enough as to attenuate the postulated cardiovascular benefits of the MedDiet. We aimed to critically review current evidence on the role of the MedDiet in cardiovascular health. We systematically searched observational prospective cohorts and randomized controlled trials which explicitly reported to assess the effect of the MedDiet on hard cardiovascular end points. We critically assessed all the original cohorts and randomized controlled trials included in the 5 most comprehensive meta-analyses published between 2014 and 2018 and additional prospective studies not included in these meta-analyses, totaling 45 reports of prospective studies (including 4 randomized controlled trials and 32 independent observational cohorts). We addressed the existing controversies on methodology and other issues. Some departures from individual randomization in a subsample of the landmark Spanish trial (PREDIMED [Prevención con Dieta Mediterránea]) did not represent any clinically meaningful attenuation in the strength of its findings and the results of PREDIMED were robust in a wide range of sensitivity analyses. The criteria for causality were met and potential sources of controversies did not represent any reason to compromise the main findings of the available observational studies and randomized controlled trials. The available evidence is large, strong, and consistent. Better conformity with the traditional MedDiet is associated with better cardiovascular health outcomes, including clinically meaningful reductions in rates of coronary heart disease, ischemic stroke, and total cardiovascular disease.   (*Circ Res*. 2019;124:779-798. DOI: 10.1161/CIRCRESAHA.118.313348.)**

Key Words: alcohol ■ clinical trials ■ cohort studies ■ meta-analysis ■ olive oil ■ polyphenols

Diet has been traditionally considered as a main determinant of cardiovascular health. In fact, one of the 7 cardiovascular health metrics proposed in 2010 by the American Heart Association (Life's simple 7) directly corresponds to a healthy diet.[1] But also, other 4 of the remaining 6 proposed health metrics (body mass index, blood pressure, total cholesterol, and blood glucose) are closely determined by dietary habits. Moreover, an additional health metric, physical activity, represents just the other side of the energy balance equation and it is indirectly related to dietary energy intake. Therefore, a healthy diet is essential to meet most of the goals of Life's simple 7 and to ensure cardiovascular health.

In this context, the overall quality of the whole food pattern may be more important and more interpretable than analyses focused on single nutrients or foods. The study of overall food patterns represents the current state of the art in the investigation of the nutritional determinants of cardiovascular health.[2,3] This approach is advantageous because it limits confounding by individual dietary factors and it captures the synergistic

effects of individual foods and nutrients. It may also provide a more powerful tool to assess the effect of dietary habits on cardiovascular health because the effect of a single dietary element is likely to be too small as to be detected in epidemiological studies or randomized controlled trials (RCTs). In contrast, it seems logical that the cumulative effect of many different aspects of diet is likely to be considerably larger.[4]

The Mediterranean diet (MedDiet) represents a salient overall dietary pattern in nutritional epidemiology that has been extensively studied, especially during the last 2 decades.

The MedDiet is defined as a traditional eating pattern found among populations living in the Mediterranean Basin during the 50s and 60s of the 20th century, but, unfortunately, not today.[5] The main characteristics of the MedDiet at those times were a low consumption of meat and meat products, with very low consumption of red meat (beef, pork, and lamb were reserved only for special occasions), very low or null consumption of processed meats, butter, ice creams, or other whole-fat dairy products (only fermented

Nonstandard Abbreviations and Acronyms	
aMedDiet	alternative Mediterranean diet
CHD	coronary heart disease
CVD	cardiovascular disease
EVOO	extra-virgin olive oil
GOSPEL	Global Secondary Prevention Strategies to Limit Event Recurrence After Myocardial Infarction
HDL-C	high-density lipoprotein cholesterol
ICAM	intercellular adhesion molecule
IL	interleukin
LDL-C	low-density lipoprotein cholesterol
MI	myocardial infarction
MUFA	monounsaturated fat
MedDiet	Mediterranean diet
PREDIMED	Prevención con Dieta Mediterránea
RCT	randomized controlled trial
RR	relative risk
SFA	saturated fat
SUN	Seguimiento Universidad de Navarra
TNF	tumor necrosis factor
VCAM	vascular cell adhesion molecule

dairy products, cheese and yogurt, were consumed in moderate amounts). It presented a relatively fat-rich profile because of the abundant consumption of olive oil, together with a high consumption of minimally processed, locally grown, vegetables, fruits, nuts, legumes, and cereals (mainly unrefined).[6] An important source of protein was a moderate consumption of fish and shellfish, that was variable depending on the proximity to the sea. The main sources of fat and alcohol among persons in the traditional MedDiet are primarily extra-virgin olive oil (EVOO) and red wine, respectively. The abundant use of olive oil, through salads, traditionally cooked vegetables, and legumes, together with the moderate consumption of red wine during meals makes this diet highly nutritious and palatable. Red wine and EVOO contain several bioactive polyphenols (hydroxytyrosol and tyrosol, oleocanthal, and resveratrol) with postulated anti-inflammatory properties.[7] Postulated antiatherogenic properties of olive oil were supposedly attributed to its high content of monounsaturated fat (MUFA; oleic acid),[8] and some more recent investigations also suggest that bioactive polyphenols, only present in the EVOO, but not in the refined-common variety of olive oil, may contribute to these cardioprotective actions.[9] EVOO is the product from the first pressing of the ripe olive fruit and contains many antioxidants (polyphenols, tocopherols, and phytosterols).[10] Lower-quality oils (refined or common olive oils) are believed to be devoid of most of these antioxidant, anti-inflammatory, or pleiotropic capacities because they are obtained by physical and chemical procedures that keep the fat but lead to the loss of most bioactive elements.

In the Spanish landmark PREDIMED trial (Prevención con Dieta Mediterránea), with 7447 high-risk participants initially free of cardiovascular disease (CVD), a 5-year intervention with a MedDiet significantly reduced the incidence of a composite major CVD end point that included nonfatal stroke, nonfatal coronary heart disease (CHD), and all fatal CVD events. However, the results of that trial were recently retracted by the authors and simultaneously republished in the same journal.[11] They included many new analyses and comprehensively addressed some small departures from individual randomization. Notwithstanding, many questions remain as to whether the MedDiet can confer benefits for cardiovascular health in both Mediterranean and non-Mediterranean populations. It is also uncertain how variations in the components of the MedDiet indices used in different studies may influence this association. In addition, other potential sources of bias should be adequately addressed.

In the first sections of this article, we will discuss some potential concerns about the beneficial cardiovascular effects of the MedDiet. In the following sections, we will address issues related to these concerns. The currently available evidence strongly supports the MedDiet as an ideal approach for cardiovascular health.

Concerns About the MedDiet

Potential Limitations Related to the Concept and Operational Definitions of the MedDiet

Is the MedDiet a Concept Promoted Mainly or Partly for Geographic-Romantic-Nostalgic Reasons?

Many of the investigators who are currently strong supporters of the MedDiet have born, live, or have an ancestry in Mediterranean countries.[6,12] This might represent a reason of concern because they may be biased when selecting the pieces of evidence that best fit in the picture of their preconceptions about what should be a healthy diet.[13] They are likely to include those aspects of their diet that they have loved since childhood and even they learnt from their grandparents or ancestors.[14] It is easy to think that there might be a sort of mixture of scientific and nonscientific reasons, some of them probably unconscious, in this group of investigators and these mixed motives may have contributed to the adoption of their strong positions and opinions on the cardiovascular benefits of the MedDiet. As discussed below, this assertion is not supported by the fact that numerous studies conducted in non-Mediterranean populations have found similar benefits of Mediterranean-type dietary patterns on CVD risk.

Is the MedDiet a Concept Based on Vested Commercial Interests of Olive Oil and Nut Companies?

The potential biases in biomedical investigation related to research funding by the pharmaceutical industry have been largely studied and documented. It is well-known that there is a significant association between industry sponsorship and pro-industry conclusions. But similar biases related to research funding by food industry have been only recently documented. Pro-industry bias in pharmaceutical research might have adverse health effects on millions of patients receiving medications, but pro-industry bias in nutrition research will have adverse health effects for absolutely everyone, with a substantially higher harm for public health. In addition, regulations are tighter for pharmaceutical research than for nutritional research.[15]

In the jungle of academic-industry interactions scientific truth—nothing more, nothing less—should be the primary aim that all should pursue.[16] This statement has been frequently repeated in the scientific environments surrounding investigators on nutrition and cardiovascular health. The primary interests of multinational food companies are to increase their profits, and consequently, to make easier the most profitable food choices. In contrast, the primary interest of public health is to make easier the healthiest choices. There is a clear clash of interests. Many published studies, particularly small trials with soft end points and reviews or commentaries, on the benefits of the MedDiet for cardiovascular health have been funded by food industries or were written after their presentation in an industry-funded meeting. Although not to the same extent than for sugar-sweetened beverages,[17] this potential conflict of interest has been specifically criticized in relationship with the very concept of the MedDiet. Richard Smith, the former editor of the BMJ, wrote "a combination of vested interests, including the International Olive Oil Council and a public relations company Oldways, which promoted the diet, has—together with the natural seductiveness of the Mediterranean region—made the diet popular".[18] These criticisms, however, do not hold water based on the fact that the vast majority of evidence on MedDiet has been funded publicly. We will discuss this issue in a later section.

Should Refined Cereals Be a Part of the MedDiet?

The currently available epidemiological evidence consistently supports the recommendation to consume less refined grains and replace them by whole grains. This replacement will reduce the risks of type 2 diabetes mellitus and CVD.[19–21] However, in the most frequently used operational definition of the MedDiet,[22] all cereals are included as a single positive item. No difference is made between refined and whole grain cereals. The assumption that all grains, including refined grains, provide cardiovascular protection might be against the current scientific evidence. Fung et al[23] modified the score developed by Trichopoulou and included only whole grain products in the alternative Mediterranean diet (aMedDiet) score. Similarly, Panagiotakos et al[24] gave the greater adherence to the MedDiet to the highest consumption of whole grain**s** (Table 1). This modification seems more consistent with current mainstream findings in nutrition science. The PREDIMED trial did not include the consumption of cereals in the MedDiet adherence screener.[25] This difference might cast doubts on the reliability of some MedDiet scores to capture a dietary pattern with the largest potential for cardiovascular health.

Can Alcohol Still Be Part of the MedDiet?

A moderate intake of alcohol has usually been considered a positive item in most of the MedDiet indexes (Table 1). However, results from a recent study have pointed out alcohol consumption as one of the leading factors for global disease burden.[26] There is a view—based on some studies with inherent limitations—that alcohol, even when consumed moderately, increases the risk of many diseases.[27] Specifically, a dose-response relationship between alcohol and different types of cancer is likely to exist.[28] For this reason, some adapted MedDiet scores have excluded alcohol intake to assess the relationship between adherence to MedDiet and breast cancer.[29]

Thus, one question is whether moderate alcohol consumption should no longer be used in the operational definition of the MedDiet. As discussed below, moderate consumption of wine with meals is still considered one of the components of MedDiet, although consumption of alcohol is not encouraged for individuals who do not drink.

Do Dairy Products Play Any Role in the MedDiet?

The role of dairy products in cardiovascular health is controversial. However, metabolic benefits have been reported for some dairy products, specially fermented dairy products in a nonlinear relationship,[30] and a meta-analysis found significant reductions in stroke incidence associated with dairy product consumption.[31] Nevertheless, all dairy products are negatively weighted in the MedDiet score proposed by Trichopoulou.[22] However, the aMedDiet and the MedDiet adherence screener excluded most dairy products giving them a null value. This is another source of discrepancy between the scores used in different studies which contributes to the consideration that the MedDiet is a broad term that varies across the literature.[32] In fact, Galbete et al[33] compiled 34 different published definitions of the MedDiet.

Are Potatoes and Eggs a Part of the Definition of the MedDiet?

In most of these 34 definitions,[33] potatoes were excluded from the vegetable group when computing the MedDiet score. But potatoes were explicitly included together with vegetables in a small number of scores, such as those used by Tognon et al[34] and by Knoops et al.[35] In other 2 reports, they were also positively weighted (as supposedly beneficial) because they were included together with cereals.[36,37]

Usually, egg consumption is not included in definitions of the MedDiet, but some studies did include eggs together with meats[38] or as a separate item giving to egg consumption a negative weight.[39]

In the landmark observational cohort study that first related the MedDiet with lower cardiovascular mortality,[22] authors explicitly stated that potatoes and eggs should be kept apart from the scoring system for the MedDiet, and therefore they should receive a null consideration.

Should Any Diet Rich in Fruit and Vegetables Be Classified as a Traditional MedDiet?

Surprisingly, some meta-analyses classified as Mediterranean any dietary pattern which met at least 2 of 7 criteria. The rationale for these criteria is more than debatable and this terminology is confusing because this would mean, for example, that any diet rich in fruit and vegetables could be called a Mediterranean-style diet.[40]

What Are the Main Sources of Fat and Fat Subtypes in the MedDiet?

In the most common definition of the MedDiet,[22] the ratio MUFA:saturated fat (SFA) is one of the 9 items used to build the score, but other scores have used instead the unsaturated:SFA ratio, including polyunsaturated fats to account for the fact that other sources of MUFA,[41] different from olive oil, are usually important in non-Mediterranean regions and the usual finding of beneficial cardiovascular effects when SFA is replaced by polyunsaturated fat. In some other

Table 1.   **Mediterranean Diet Scores Frequently Used in Cardiovascular Research**

	Mediterranean Diet Score (Trichopoulou et al,[22] 0 to 9 Points)	Alternate Mediterranean Diet Score (Fung et al,[23] 0 to 9 Points)	Mediterranean Diet Score (Panagiotakos et al,[24] 0 to 50 Points)	MEDAS (MEDAS-PREDIMED,[25] 0 to 14 Points)
Positively weighted components	Monounsaturated/saturated*	Monounsaturated/saturated†	Olive oil in cooking‡	Olive oil as main culinary fat
	Vegetables*	Vegetables†	Vegetables‡	≥4 tablespoon§/d olive oil
	Fruits and nuts*	Fruits†	Fruits‡	≥2 servings/wk olive oil sauce with tomato, garlic, onion, or leek (sofrito)
	Legumes*	Nuts†	Legumes‡	≥2 servings/d vegetables
	Fish*	Legumes†	Fish‡	≥3 servings/d fruits
	Cereals*	Fish†	Whole grains‡	≥3 servings/wk nuts
		Whole grains†		≥3 servings/wk legumes
				≥3 servings/wk fish
				Preference for poultry (chicken, turkey, or rabbit) > red meats (beef, pork, hamburgers, or sausages)
Negatively weighted components	Meat/meat products‖	Red and processed meat¶	Red and processed meat‡	<1/d red/processed meats
	Dairy products‖		Poultry‡	<1/d butter/margarine/cream
			Full-fat dairy products‡	<1/d carbonated/sugar-sweetened beverages
				<2/wk commercial bakery, cakes, biscuits, or pastries
Alcohol	5–25 g/d (women)	5–15 g/d (women)	>0 and <300 mL/d (5 points)	≥7 glasses#/wk of wine
	10–50 g/d (men)	10–25 g/d (men)		

MEDAS-PREDIMED indicates Mediterranean Diet Adherence Screener-Prevención con Dieta Mediterránea.

*One point if the consumption was at or above the sex-specific median.

†One point if the consumption was above the sex-specific median.

‡0 to 5 points according to 6 categories for frequency of consumption.

§One tablespoon=13.5 g.

‖One point if the consumption was below the sex-specific median.

¶One point if the consumption was at or below the sex-specific median.

#One glass=100 mL.

Mediterranean scores, instead of using the MUFA:SFA ratio, the authors selected only the consumption of olive oil for this item. Even if olive oil might not correspond to the most important source of fat for cardiovascular health, use of olive oil as main culinary fat is an essential characteristic of the MedDiet. The PREDIMED trial gave a special importance to EVOO as a source of bioactive polyphenols. These polyphenols are increasingly mentioned as contributors to the cardiovascular health benefits because of their anti-inflammatory properties.[42,43] Interestingly, the 14-item questionnaire used in the PREDIMED was one of the scores that captured the highest intake of polyphenol antioxidant content in a comparison of 21 MedDiet indexes.[44]

Are Polyphenols Consumed in Sufficient Amounts as to Have a Credible Effect?

There are differences between Mediterranean and non-Mediterranean countries about the type of flavonoids and food sources.[45] But when a high polyphenol content of the MedDiet is invoked as partly responsible for the cardiovascular benefits of this food pattern, a relevant question is usually raised: what are the minimum amounts of bioactive polyphenols that can exert a sufficiently large pleiotropic effect as to yield meaningful

clinical effects? One of the substudies of PREDIMED measured total polyphenol urinary excretion and the lower limit for the upper tertile of excretion was 32 mg gallic acid equivalent per gram of creatinine.[46] How is it possible that these polyphenols which are present only in minuscule amounts may be able to account for an impressive reduction in cardiovascular clinical events? This quantitative question that was critical when postulating resveratrol as the main element responsible for the potential protective effect of red wine has not been sufficiently investigated with respect to the total amounts of polyphenols present in the typical foods of the MedDiet. However, polyphenols are only a part of the synergy among many beneficial bioactive compounds in the MedDiet.

Are the Sample-Specific Cutoff Points Used for Some MedDiet Scores Valid?

The usual approach to derive scores of adherence to the MedDiet is to use the sample-specific medians of consumption of each food group, and to assign one point to those who are at or above the sex-specific median of the sample for items that are in line with the concept of the traditional MedDiet. On the contrary, one point is given to those participants who are below the sex-specific median of consumption for items that

are in opposition to the traditional MedDiet. In some other scores, the authors used tertiles (to give 2, 1, or 0 points) instead of using the dichotomization at the sample medians.[47]

A potential problem with these scoring systems is that the medians (or other quantiles) are dependent on the sample characteristics and can compromise between-study comparisons or its generalizability.

Why So Many Disparate Scores?

A relevant question seems to be the disparate classification and the many different actual exposures that have been collectively classified under the same term MedDiet. The most recent systematic review[33] assessed 70 original studies (including both cardiovascular and noncardiovascular outcomes). Among them, 14 studies used the definition of Trichopoulou, and 18 other studies used definitions (9 different versions), that were basically similar to the Trichopoulou definition.[22] The aMedDiet proposed by Fung[23] (or several closely related versions) was used by 14 studies. Other definitions and scores were less frequently used. This variability entails a potential for misclassification.

Limitations in the Available Meta-Analyses of Observational Studies

There Are More Systematic Reviews Than Original Studies

In 2016, an evaluation of the quality of systematic reviews relating the MedDiet with cardiovascular outcomes was published by Huedo-Medina et al.[32] They included 24 meta-analyses and systematic reviews in their evaluation. In 2015, Martínez-González et al[48] included 37 meta-analyses or systematic reviews assessing the association between adherence to the MedDiet and cardiometabolic outcomes. Subsequently, in 2017 and 2018, 5 new meta-analyses or systematic reviews were published.[33,49–52] Most of the available systematic reviews included <25 original studies. Therefore, paradoxically, the literature seems to contain more reviews than original studies (Table 2).[32,33,48–59,61–65,68–70,74–77,81,86,87,90–96,100,101,122,123] A summary description is shown in Table 2 and the overlapping original studies[22,23,34,37–39,41,60,66,67,71–73,78–80,82–84,88,97,98,102–104,108–115,117–121,124–129] between systematic reviews are presented in Figure 1.

Some of the Available Meta-Analyses Were Rated as Low Quality

The quality assessment conducted by Huedo-Medina et al[32] reported that on average, systematic reviews on MedDiet and cardiovascular health achieved a low-quality score and 60% of the 24 reviews presented limitations because they did not report the search details or used inappropriate statistical methods. Only 42% used appropriate statistical methods to combine the findings.[32] This weakness does not pertain to the original studies, but to the meta-analytic methods.

Sources of Heterogeneity in Meta-Analyses

Rather than establishing an artificial summary estimate of the effect of the MedDiet on cardiovascular health across a set of several disparate studies, the primary aim of a meta-analysis should have been to identify and estimate the differences among study-specific effects (ie, an analytical goal).[130] This is especially important in the field of MedDiet and cardiovascular health because of the need to deal with studies using

different definitions of exposure, different outcomes, different methodology, and different geographic or demographic origins. The major goal should be to assess whether these characteristics determine a different result. In 1 meta-analysis,[81] 5 out of the 16 estimates were the main source of heterogeneity because they only assessed fatal outcomes. When these 5 estimates were removed, the heterogeneity disappeared and the effect became slightly stronger. More recently, Rosato et al[49] assessed sources of heterogeneity and found an overall relative risk (RR) for CVD of 0.61 (95% CI, 0.44–0.86) for 2 studies conducted in Mediterranean regions and 0.84 (95% CI, 0.77–0.92) for the 8 original studies conducted outside the Mediterranean area (P for heterogeneity=0.11). Also, other candidate variables did not show any significance in the heterogeneity test. Galbete et al[33] reported that studies using the Trichopoulou MedDiet score[22] showed a stronger inverse association (RR, 0.87; 95% CI, 0.83–0.91 for high versus low adherence) compared with studies using the aMedDiet score (RR, 0.92; 95% CI, 0.89–0.94), with only marginal heterogeneity (P=0.06).

Publication Bias

Statistically significant studies going in the expected direction are more likely to be published.[131] This fact is the source of publication bias that represents a major threat for the validity of systematic reviews. Huedo-Medina et al[32] criticized that only one-fourth of the systematic reviews that they evaluated assessed publication bias. Rosato et al[49] reported that the Begg and Egger tests conducted to assess publication bias, respectively, gave P values of 0.087 and 0.034 for CHD, 0.13 and 0.008 for unspecified stroke, and 0.44 and 0.27 for unspecified CVD, showing a potential for publication bias for CHD and unspecified stroke. This might represent a concern. However, most of these P values were not significant.

Limitations of the Available RCTs

Strengths and Limitations of the Lyon Trial: Too Good to Be True?

The French Lyon Diet Heart study was a landmark trial in the study of diet and cardiovascular health.[97] It was a secondary prevention trial aimed at reducing the risk of cardiovascular deaths and recurrent myocardial infarction (MI) by diet modification in 605 patients, survivors of a previous MI and recruited between 1988 and 1992. Patients were randomized to a Mediterranean-type diet (302 patients) or to a control group (303 patients). In the active intervention group, patients were encouraged to increase their consumption of fruit (no day without fruit), vegetables, bread, and fish. They were also advised to reduce the consumption of red meat (beef, pork, and lamb should be replaced by poultry), and to replace butter and cream by a special margarine, much richer in alpha-linolenic acid than olive oil (4.8% versus 0.6% of alpha-linolenic acid), but, with 48% oleic acid, low content of saturated fatty acids and, slightly higher content of linoleic acid (16.4% versus 8.6%) than olive oil. Control subjects were allocated the usual care by their physicians, who recommended a diet similar to the low-fat step-1 diet of the American Heart Association. The results of the Lyon Diet Heart Study were impressive, but the intervention did not exactly correspond to the traditional MedDiet.

Table 2.   Summary of the Reviews and Meta-Analyses Gathering Evidence About Mediterranean Diet and CVD

Author	Systematic	Design (Assessed Designs)	Outcomes	Meta-Analyzed Articles	Results (Meta-Analysis)
de Lorgeril et al[53]	No	Narrative	CHD		
Panagiotakos et al[54]	Yes	Case-control and prospective studies	CHD		
Serra-Majem et al[55]	Yes	Trials	CVD		
Willett[56]	No	Personal perspectives			
de Lorgeril et al[57]	No	Narrative			
Roman et al[58]	Yes	Any design, participants older than 65	CVD		
Sofi et al[59]	Yes	Cohort studies	CVD mortality	22,35,60	0.91 (0.87–0.95)
Martínez-González et al[61]	No	Narrative	Chronic diseases		
Mente et al[62]					
Sofi[63]	No	Narrative	Health outcomes		
Sofi et al[64]	Yes	Cohort studies			
Tyrovolas et al[65]	Yes	Observational studies	CVD incidence or mortality	22,23,35,60,66,67	0.90 (0.87–0.93)
McKeown et al[68]	No	Narrative	CVD and CHD		
Foroughi et al[69]	Yes	Observational studies, trials, reviews, and meta-analyses	Stroke		
Psaltopoulou et al[70]	Yes	Observational	Stroke	23,71,72,73	0.84 (0.74–0.95)
Rees et al[74]	Yes	Trials and primary prevention	CVD	Authors did not find any trial	…
de Lorgeril[75]	No	Narrative	CVD		
Grosso et al[76]	Yes	Epidemiological studies	CVD and risk factors		
Kontogianni et al[77]	Yes	Observational and trials	Stroke	78,79,80	0.68 (0.58–0.79)
Martínez-González et al[81]	Yes	Cohorts and trials	CVD	82,78	RCTs: 0.64 (0.53–0.79)
				23,34,35,38,60,66,72,83,84,79,85	Observational: 0.90 (0.86–0.94)
Ros et al[86]	No	Narrative	CVD		
Sofi et al[87]	Yes	Prospective studies	CVD incidence or mortality	23,34,35,36,37,60,71,88,72,83,73, 79,85,89	0.90 (0.87–0.92)
Trichopoulou et al[90]	No	Narrative			
Whayne[91]	No	Narrative	Ischemic heart disease		
Sleiman et al[92]	Yes	Cross-sectional, prospective, and controlled clinical trials	CVD, CVD mortality, and PAD		
Widmer et al[93]	No	Narrative	CVD		
D'Alessandro et al[94]	No	Narrative	CVD		
Shen et al[95]	No	Narrative	CVD, AF, and CVD mortality		
Martínez-González et al[48]	No	Narrative	CVD and CVD mortality		
Huedo-Medina et al[32]	Yes	Systematic reviews and meta-analyses	CVD outcomes		
Liyanage et al[96]	Yes	RCTs	CVD mortality	97,98,78,99	0.90 (0.72–1.11)
			Coronary events	97,98,78	0.65 (0.50–0.85)
			Stroke	98,78	0.66 (0.48–0.92)
			HF	97,98	0.25 (0.05–1.17)

(*Continued*)

Table 2.   Continued

Author	Systematic	Design (Assessed Designs)	Outcomes	Meta-Analyzed Articles	Results (Meta-Analysis)
Martínez-González et al[100]	No	Prospective studies and RCT	CVD		
Bloomfield et al[101]	Yes	Controlled trials	CVD	78	
Dinu et al[52]	Yes	Meta-analyses of observational studies and randomized trials	CVD and health outcomes		
Rosato et al[49]	Yes	Observational studies	CHD and MI	34,66,72,83,73,102,103,104,85,105,106,71,73,79,80,104,107,23,71,72,108,103	0.70 (0.62–0.80)
			Unspecified stroke	23,71,108,103	0.73 (0.59–0.91)
			i-stroke	35,37,88,72,73,109,110,104,111,112,85	0.82 (0.73–0.92)
			h-stroke		1.01 (0.74–1.37)
			Unspecified CVD		0.81 (0.74–0.88)
Martínez-González et al[50]	Yes	Clinical trials or prospective cohort studies	CVD incidence or mortality	22,23,34,35,38,97,78,60,66,88,72,83,73,79,103,113,114,111,115,85,116	0.89 (0.86–0.91)
Grosso et al[51]	Yes	Prospective studies and RCT	CVD incidence	23,38,39,117,66,71,72,67,83,73,84,79,118	0.73 (0.66–0.80)
			CVD mortality	23,34,35,38,60,88,119,83,73,84,79,102,120	0.71 (0.65–0.78)
			CHD incidence	23,66,110,85	0.72 (0.60–0.86)
			MI incidence	38,72,73	0.67 (0.54–0.83)
			Stroke incidence	23,38,71,72,73	0.76 (0.60–0.96)
			MI (RCT)	98,78,121	0.60 (0.44–0.82)
			Stroke (RCT)	78,121	0.64 (0.47–0.86)
			CVD mortality (RCT)	82,98,78,121	0.59 (0.38–0.93)
			Composite (RCT)	82,98,78,121	0.55 (0.39–0.76)
Galbete et al[33]	Yes	Systematic reviews and meta-analyses	CVD and chronic diseases		
Martinez-Lacoba et al[122]	Yes	Reviews and meta-analyses	CVD and other health outcomes		
Salas-Salvadó et al[123]	No	Narrative	CVD		

AF indicates atrial fibrillation; CHD, coronary heart disease; CVD, cardiovascular disease; HF, heart failure; h-stroke, hemorrhagic stroke; i-stroke, ischemic stroke; MI, myocardial infarction; PAD, peripheral artery disease; and RCT, randomized controlled trial.

The trial showed a dramatic reduction in major coronary events and deaths, that was maintained over a 4-year follow-up period.[82] In an interim analysis at 27 months of follow-up, there was a 73% reduction in coronary events and a 70% reduction in total mortality and the study was stopped early.[132]

Other methodological limitations of the Lyon trial have been highlighted.[61,133] As, apparently, there was no prespecified stopping rule, it is likely that early stopping of the trial would have led to an overestimation of the effect.[134] Baseline diet was only assessed in the experimental group but not in the control group and, consequently, it was impossible to assess the dietary changes that occurred in the control group. Information on diet at the end of the trial was reported for only 27% of the control group and only 48% of the experimental group. Very importantly, no sufficient consideration was given in the Lyon trial to the pivotal role of olive oil in the traditional MedDiet. The fat composition among evaluated participants of the experimental group in the Lyon trial was 30.5%

of energy intake as total fat (12.9% MUFA). This value for MUFA intake is below 15 to 20% MUFA content from olive oil usually present in the traditional MedDiet. The Lyon trial included only subjects with a previous coronary event (it was a secondary prevention trial). Primary and secondary prevention trials are different because mortality or relapses of CHD are not only related to CHD incidence but also to the quality and timeliness of medical care.[135]

Scarce Reliability of the Indo-Mediterranean Trial

Lancet published in 2002 the results of the Indo-Mediterranean trial[98] reporting a dramatic reduction in the incidence of cardiovascular outcomes in 499 patients randomly allocated to a diet rich in whole grains, fruits, vegetables, walnuts, and almonds as compared with 501 controls allocated to the consumption of a local diet similar to the low-fat Step I National Cholesterol Education Program diet. But subsequently, in 2005, Lancet issued an expression of concern because of the failure to locate original research records.[136] Though this study

Figure 1. Overlapping studies between systematic reviews.

is still sometimes included in both narrative and systematic reviews, it has been largely discredited, and it should be considered at least as a severely flawed investigation.

Deviations From the Individual Randomization Protocol in the PREDIMED Trial

The Spanish PREDIMED trial included 7447 participants at high cardiovascular risk allocated to 1 of 3 diets: a MedDiet supplemented with EVOO, a MedDiet supplemented with mixed nuts, or a control diet (advice to reduce all subtypes of dietary fat). The trial was planned for 6 years, but it stopped early after intervention for 4.8 years, as recommended by the Data and Safety Monitoring Board following stopping rules established a priori in the protocol.[11,48,137,138] The incidence of CVD (MI, stroke, or cardiovascular death, totaling 288 events) in the MedDiet groups was lowered by ≈30% when compared with the control diet.

PREDIMED is a landmark study and it remains to date as the largest dietary intervention trial to assess the effects of the MedDiet on CVD prevention. However, a review published in June 2017 identified the PREDIMED trial as having distributions that were significantly different from those expected from randomization.[139] This report prompted the Investigators of PREDIMED to take the initiative to contact the editors of *The New England Journal of Medicine*. After July 2017, the

investigators of PREDIMED identified 2 departures from the reporting or application of the protocol:

1. The allocation by clusters (by small clinics), instead of individual allocation of some participants at 1 of 11 study sites (site D), affecting 467 participants (6.2% of total PREDIMED participants) in 11 clinics (2 allocated to MedDiet+EVOO, 5 allocated to MedDiet+nuts, and 4 allocated to control). In another site (site I), with 1094 participants recruited from 37 small clinics, the research team of that site conducted the intervention in participants from 11 clinics for only one arm of the trial in each clinic (on a total of 247 participants, 22.6% in this site). They also reported that an apparent inconsistent use of randomization tables was done at another site (site B). However, baseline characteristics were well balanced in sites I and B.

2. Enrollment of household members (partners of a previous participant) without randomization; members of the household of randomized participants were invited to participate and allocated to the same intervention group as their relatives. The second enrolled partners of a previous participant represented 5.7% of PREDIMED participants, with a slightly lower proportion in the control group (4.82%) than in the MedDiet group+EVOO (6.72%) or the MedDiet group+nuts (5.54%). This was done to avoid assigning members of the same household to different diets. Assigning all participants in a

household to the same diet was viewed as the best approach to achieve dietary changes in the household. This procedure was inadvertently omitted in the reporting of the protocol and the original publication.

Baseline imbalances were minor and consisted only in a slightly higher percentage of women in the control group (5.7% higher in control than in the MedDiet+nuts group and 1% higher in control than in the MedDiet+EVOO group) and a 5.3% higher percentage of patients with high levels of LDL-C (low-density lipoprotein cholesterol) in the MedDiet+EVOO than in the control group. Interestingly, both would be in any case operating against the hypothesis of the trial and therefore cannot provide any alternative noncausal explanation of the PREDIMED findings. Several criticisms were raised after these departures from the protocol were disclosed.[140]

The investigators of PREDIMED decided to retract their original article,[78] and simultaneously republished a new version in the same journal,[11] where these issues were fully addressed. The republication included the results of many new sensitivity and ancillary analyses that showed no changes with respect to the original results of PREDIMED.[11]

Strengths of the MedDiet

All the previous considerations represent potential caveats and drawbacks threatening the validity of the MedDiet paradigm for cardiovascular health. There are also many strengths in the currently available evidence to support the validity of the proposal defending the MedDiet model as the ideal approach for cardiovascular health.

The MedDiet possesses a millenary tradition of use without any evidence of harm.[56] Current definitions of the MedDiet are in line with traditional food patterns followed in Mediterranean areas during the 50s and 60s of the past century, where life expectancies after 45 years were among the highest of the world.[141]

The pioneer epidemiological study supporting the MedDiet for cardiovascular health was not conducted by anybody living in the Mediterranean area or with a Mediterranean ancestry. These first pieces of evidence came from the Seven Countries Study, an ecological, international, investigation of diet, and cardiovascular disease in 16 groups totaling nearly 13 000 men in 7 countries (Greece, Italy, Japan, Finland, the former Yugoslavia, the Netherlands, and the United States). This study was started in 1958 by an American investigator, Keys[142] (Figure 2). He was the one who developed and promoted for the first time the concept of the cardioprotective MedDiet. Therefore, it is not likely that geographic-nostalgic-romantic motivations related to the diet learnt by some investigators in their childhood from their grandparents might be at the root of this concept. Keys was a physiologist and epidemiologist at the University of Minnesota who discovered the cardiovascular health benefits of the MedDiet in the early 1950s, when he visited Mediterranean countries as a scientist concerned on the rapidly growing trend of coronary mortality in the United States.[143] Keys did his first research on the MedDiet by studying in situ the dietary patterns of men in Italy, Spain, and Crete and their association with cardiovascular health,

with special emphasis on the effects of dietary fat and fatty acids on serum cholesterol levels and CVD risk. His findings were particularly prominent about the importance of fat subtypes—and not of total fat intake—and the relevance of the MUFA:SFA ratio. The MedDiet relatively rich in fat (even to levels of 40% of calories from fat) but with an optimal MUFA:SFA ratio appeared as an ideal model for cardiovascular health. All these facts were in accordance with the long-lasting experience of use of this dietary pattern in relatively poor sectors of the world with high rates of smoking and, nevertheless, with a very-low-CHD mortality.

Paradigm of Dietary Patterns Has Many Advantages

In contrast with the classical analytical approach of only assessing exposures to single nutrients or isolated food items, the study of overall dietary patterns has become the current prevalent framework in nutrition research. This approach has been fully adopted and endorsed by the 2015 Dietary Guidelines Advisory Committee.[144] The food pattern approach is advantageous for many reasons: (1) because food items and nutrients could have synergistic or antagonistic effects when they are consumed in combination; (2) overall food patterns represent the current practices found in the assessed population (people do not eat isolated nutrients) and, therefore, they better capture the actual exposure of interest; (3) they provide useful sociological information of great interest in itself for public health; (4) the use of dietary patterns as the relevant exposure in nutrition reduces the potential for confounding by other dietary exposures; and (5) very importantly, the focus on the overall food pattern seems clearly superior to the reductionist and overly optimistic assumption of attributing all the effect to a single nutrient or food. It would seem very unlikely that a single nutrient or food could exert a sufficiently strong effect as to substantially change the rates of cardiovascular outcomes. In contrast, the additive effect of small changes in many foods and nutrients seems to exert a more biologically plausible and clinically meaningful effect. In fact, during the last 2 decades, numerous well-conducted prospective epidemiological studies have confirmed strong relationships between a priori defined high-quality dietary patterns and a lower risk of chronic disease, including cardiovascular clinical outcomes. As one of the members of the 2015 Dietary Guidelines Advisory Committee recently highlighted, hypothesis-oriented patterns based on available scientific evidence for chronic disease are an attractive alternative, because the use of an a priori scoring system offers a consistent metric that can be applied across multiple studies and the consistency in methods then allows comparisons of results across populations.[144] In this context, as Figure 3 shows, the MedDiet pyramid[145] includes many different foods with specific recommendations for their consumption on every main meal, daily, weekly, or less frequently. Consequently, the MedDiet fits very appropriately in the paradigm of overall dietary patterns and it represents one of the best-known models for this paradigm. Moreover, the MedDiet was explicitly endorsed by the 2015 Dietary Guidelines Advisory Committee after reviewing all the available scientific evidence.[146]

Figure 2. Historical and scientific milestones of the Mediterranean diet (MedDiet) and its cardiovascular benefits. PREDIMED indicates Prevención con Dieta Mediterránea; UNESCO, United Nations Educational, Scientific and Cultural Organization; and WHO, World Health Organization.

Variety of Definitions Had Little Impact on the Cardiovascular Health Effects

It would be desirable to adopt a universal definition of MedDiet for the sake of comparability among different studies in the future. The use of different definitions does not help to assess the consistency among studies nor to translate the scientific research into practical recommendations for the general population.[147] Notwithstanding, in Figure 4, we standardized the comparisons to represent the association for a 22.2% increment in the used score, equivalent to a 2-point increment in the 0 to 9 score proposed by Trichopoulou.[22] However, it should be acknowledged that

the groupings used in the studies shown in Figure 4 do not represent always the same comparison, because of the previously mentioned diversity in the content of the different indexes. This should be taken into account when interpreting the results summarized in Figure 4.

The use of sample quantiles as cutoff points to compute the MedDiet scores might be seen as a limitation because they depend on sample characteristics. However, this approach can present also advantages because using quantile-defined categories instead of a priori defined cutoff points is in better agreement with characteristics of food-frequency questionnaires and other dietary assessment tools which are better

Figure 3. First and last version of the Mediterranean diet (MedDiet) pyramid developed by Oldways.

study	RR (95% CI)	outcome
Trials		
de Lorgeril, 1994 [86]	0.24 (0.07, 0.84)	CVD mort
de Lorgeril, 1994 [86]	0.27 (0.12, 0.60)	CVD mort+MI
PREDIMED, 2013 (ITT) [11, 89]	0.70 (0.55, 0.89)	Combined
PREDIMED, 2013 (ITT) [11, 89]	0.58 (0.42, 0.81)	Stroke
PREDIMED, 2013 (ITT) [11, 89]	0.80 (0.53, 1.21)	MI
PREDIMED, 2013 (ITT) [11, 89]	0.80 (0.51, 1.25)	CVD mort
PREDIMED, 2018 (PP) [11]	0.42 (0.26, 0.68)	Combined
Cohorts		
Trichopoulou, 2003 [36]	0.67 (0.47, 0.95)	CHD mort
Knoops, 2004 [35]	0.87 (0.80, 0.95)	CVD mort
Knoops, 2004 [35]	0.82 (0.71, 0.95)	CHD mort
Trichopoulou, 2005 [41]	0.69 (0.52, 0.92)	Cardiac mort
Mitrou, 2007 [95]	0.91 (0.86, 0.95)	CVD mort
Mitrou, 2007 [95]	0.92 (0.86, 0.99)	CVD mort
Panagiotakos, 2008 [96]	0.47 (0.30, 0.74)	CHD+stroke
Buckland, 2009 [98]	0.78 (0.69, 0.89)	CHD
Buckland, 2009 [98]	0.78 (0.68, 0.90)	MI
Fung, 2009 [23]	0.86 (0.81, 0.91)	CHD
Fung, 2009 [23]	0.90 (0.83, 0.97)	f-CHD
Fung, 2009 [23]	0.78 (0.70, 0.88)	nf-CHD
Fung, 2009 [23]	0.94 (0.87, 1.01)	Stroke
Fung, 2009 [23]	0.97 (0.88, 1.08)	i-stroke
Fung, 2009 [23]	0.90 (0.76, 1.07)	h-stroke
Fung, 2009 [23]	0.85 (0.70, 1.03)	f-stroke
Fung, 2009 [23]	0.95 (0.88, 1.03)	nf-stroke
Chrysohoou, 2010 [39]	0.36 (0.12, 1.05)	CHD+stroke
Sjögren, 2010 [37]	0.66 (0.46, 0.96)	CVD mort
Agnoli, 2011 [99]	0.54 (0.37, 0.79)	Stroke
Agnoli, 2011 [99]	0.44 (0.26, 0.76)	i-stroke
Agnoli, 2011 [99]	0.58 (0.29, 1.15)	h-stroke
Buckland, 2011 [100]	0.77 (0.66, 0.91)	CVD mort
Gardener, 2011 [101]	0.88 (0.71, 1.10)	MI
Gardener, 2011 [101]	1.00 (0.82, 1.22)	i-stroke
Gardener, 2011 [101]	0.83 (0.72, 0.95)	CVD mort
Gardener, 2011 [101]	0.90 (0.80, 1.01)	Combined
Hodge, 2011 (M) [102]	0.88 (0.79, 0.98)	CVD mort
Hodge, 2011 (F) [102]	0.88 (0.76, 1.03)	CVD mort
Scarmeas, 2011 [91]	0.81 (0.65, 1.01)	CBVD
Martínez-González, 2011 [103]	0.74 (0.55, 0.99)	CHD
Martínez-González, 2011 [103]	0.80 (0.62, 1.03)	Combined
Dilis, 2012 [104]	0.92 (0.83, 1.01)	CHD incid
Dilis, 2012 [104]	0.78 (0.66, 0.92)	CHD mort
Guallar-Castillon, 2012 [90]	0.92 (0.85, 0.98)	CHD
Hoevenaar-Blom, 2012 [105]	0.86 (0.79, 0.93)	MI
Hoevenaar-Blom, 2012 [105]	0.88 (0.78, 1.00)	Stroke
Hoevenaar-Blom, 2012 [105]	0.91 (0.78, 1.06)	PAD
Hoevenaar-Blom, 2012 [105]	0.95 (0.92, 0.99)	CVD
Hoevenaar-Blom, 2012 [105]	0.78 (0.69, 0.88)	CVD mort
Hoevenaar-Blom, 2012 [105]	0.85 (0.80, 0.91)	Combined
Menotti, 2012 (20y) [106]	0.74 (0.55, 0.99)	CHD mort
Misirli, 2012 [107]	0.85 (0.75, 0.97)	CBVD incid
Misirli, 2012 [107]	0.88 (0.73, 1.06)	CBVD mort
Misirli, 2012 [107]	0.78 (0.61, 1.00)	i-CBVD incid
Misirli, 2012 [107]	0.94 (0.69, 1.28)	h-CBVD incid
Tognon, 2012 [37]	0.93 (0.85, 1.02)	CVD mort
Tognon, 2012 [37]	0.90 (0.78, 1.02)	f-MI
Tognon, 2012 [37]	0.98 (0.82, 1.18)	f-stroke
Martínez-González, 2012 [108]	0.59 (0.36, 0.96)	CVD mort
Chan, 2013 (M) [110]	0.79 (0.62, 0.99)	Stroke
Chan, 2013 (F) [110]	0.88 (0.60, 1.28)	Stroke
Hoevenaar-Blom, 2014a [111]	0.83 (0.69, 0.99)	CVD incid
Hoevenaar-Blom, 2014a [111]	0.69 (0.47, 1.02)	CVD mort
Hoevenaar-Blom, 2014b [93]	0.94 (0.86, 1.02)	CVD incid
Hoevenaar-Blom, 2014b [93]	0.85 (0.70, 1.04)	CVD mort
Tognon, 2014 [38]	0.88 (0.81, 0.96)	CVD incid
Tognon, 2014 [38]	0.81 (0.67, 0.99)	nf-MI
Tognon, 2014 [38]	0.88 (0.73, 1.06)	nf-stroke
Tognon, 2014 [38]	0.76 (0.65, 0.90)	CVD mort
Tognon, 2014 [38]	0.66 (0.48, 0.90)	f-MI
Tognon, 2014 [38]	0.95 (0.64, 1.41)	f-stroke
Bertoia, 2014 [111]	0.84 (0.71, 0.99)	SCD
Lopez-Garcia, 2014 [112]	0.96 (0.89, 1.04)	CVD mort
Reedy, 2014 (M) [113]	0.91 (0.90, 0.93)	CVD mort
Reedy, 2014 (F) [113]	0.91 (0.88, 0.93)	CVD mort
George, 2014 [114]	0.91 (0.85, 0.97)	CVD mort
Tsivgoulis, 2015 [115]	0.90 (0.81, 1.01)	i-stroke
Tsivgoulis, 2015 [115]	0.83 (0.62, 1.11)	h-stroke
Tektonidis, 2015 [116]	0.86 (0.81, 0.92)	MI
Tektonidis, 2015 [116]	0.90 (0.85, 0.95)	HF
Tektonidis, 2015 [116]	0.90 (0.83, 0.97)	i-stroke
Tektonidis, 2015 [116]	0.88 (0.75, 1.02)	h-stroke
Sotos-Prieto, 2015 [117]	0.91 (0.86, 0.97)	CVD
Panagiotakos, 2015 [118]	0.78 (0.50, 1.22)	CVD
Bo, 2016 [119]	0.71 (0.55, 0.91)	CVD incid
Bo, 2016 [119]	0.77 (0.57, 1.05)	CVD mort
Tong, 2016 [120]	0.94 (0.90, 0.98)	CVD
Bellavia, 2016 [121]	0.91 (0.87, 0.95)	CVD mort
Stefler, 2017 [122]	0.83 (0.70, 0.99)	CVD mort
Stefler, 2017 [122]	0.83 (0.66, 1.06)	CHD mort
Stefler, 2017 [122]	0.79 (0.55, 1.12)	f-stroke
Bonaccio, 2018 [93]	0.90 (0.79, 1.04)	CVD mort
Bonaccio, 2018 [93]	0.83 (0.69, 0.99)	f-CAD/CBVD
Paterson, 2018 [94]	0.93 (0.88, 0.97)	Stroke

.25   .5   1   2
Reduced risk   Increased risk

Figure 4. Adherence to the Mediterranean diet (MedDiet) and cardiovascular disease (CVD) in prospective studies (cohorts and trials). CBVD indicates cerebrovascular disease; CHD, coronary heart disease; f, fatal; HF, heart failure; h-stroke, hemorrhagic stroke; i-stroke, ischemic stroke; ITT, intention-to-treat; MI, myocardial infarction; mort, mortality; nf, nonfatal; PP, per-protocol; and RR, relative risk.

suited to rank individuals than to accurately measure absolute intakes.[50] Therefore, the wider use of a score based on medians (or its variants using tertiles) should not be viewed as any major problem.

Moreover, when Rosato et al[49] restricted their meta-analysis to the studies using only the initial definition proposed in 2003 by Trichopoulou,[22] and they compared highest versus lowest categories, they obtained an RR of 0.82 (95% CI,

0.70–0.97) for CVD. Interestingly, similar results were found for studies using other scores different from the score proposed by Trichopoulou, with an RR of 0.80 (95% CI, 0.73–0.87) with no evidence of heterogeneity between both set of studies (*P*=0.52).[49] Analogous similarities without evidence of heterogeneity were found for CHD (*P* [heterogeneity]=0.63) and stroke (*P* [heterogeneity]=0.85). Therefore, there is no evidence to support that the differences in the definitions of the MedDiet may have affected the available results on cardiovascular health.

Light-to-moderate alcohol consumption is one item used in most of the MedDiet scores reflecting a common tradition in Mediterranean countries. This moderate consumption (1 or 2 drinks/day) has been consistently associated with a lower risk of CVDs.[148] Moreover, a Mediterranean alcohol-drinking pattern is characterized by a moderate consumption of alcohol, with preference of fermented drinks instead of spirits. This pattern emphasizes the consumption of red wine during meals.[149] This level of alcohol consumption in the context of a MedDiet probably contributes to the synergistic effect of other components of the MedDiet with similar cardioprotective mechanisms such as increasing HDL-C (high-density lipoprotein cholesterol), decreasing platelet aggregation, promoting antioxidant effects, and reducing inflammation.[150,151]

Very importantly, the use of varied and disparate operational definitions and scores to capture the construct of the MedDiet will represent a potential for nondifferential misclassification in individual original studies and a source of heterogeneity in meta-analyses. Both factors most likely will tend to attenuate the associations towards the null value. This attenuation of effects may concur with other aspects of the definitions that may mainly represent a tendency to underestimate the effects. For example, the exclusion of all dairy products in the Trichopoulou score may lead to losing the potential cardiometabolic benefits of yogurt consumption and may attenuate the estimates of RR. Similarly, the inclusion of potatoes in the group of vegetables or the inclusion of refined grains in the group of cereals would also produce an attenuating effect, as it was specifically shown in the SUN (Seguimiento Universidad de Navarra) cohort, where the group of cereals and, specifically white bread, showed an association with higher risk of CVD.[85] As all these issues related to different criteria for the selection of food items in the operational definitions of MedDiet will potentially tend to attenuate the protective effects, it seems very unlikely that the consistent inverse association for the MedDiet with cardiovascular clinical events reported by many studies can be alternatively explained by the use of disparate criteria for computing the operational definitions and scores.

Causality Criteria Are Met

The 9 classical criteria for supporting causality proposed half a century ago by Hill[152] are met for the effect of the MedDiet on cardiovascular health. Bradford Hill stated that "none of my nine viewpoints can bring indisputable evidence for or against the cause-and-effect hypothesis and none can be required as a sine qua non. What they can do, with greater or less strength, is to help us make up our minds on the fundamental question- is there any other way of explaining the set of facts before us, is there any other answer equally, or more, likely than cause and effect?".[152] However, the criterion of temporal sequence should be viewed as a sine qua non element. The application of these 9 principles to the association between better conformity to the MedDiet and a causal effect to reduce the risk of cardiovascular events is as follows.

1. Temporal sequence: The design of the studies included in this review are prospective cohorts and RCT that provide a strong evidence for an adequate temporal sequence, because in all of them the exposure (MedDiet) clearly preceded the end point (CVD).

2. Strength of the association: A MedDiet relatively reduced the incidence of major CVD events by 30% after using an intention-to-treat approach, and attained even a higher reduction in a per-protocol analysis in the PREDIMED trial.[11] Findings are in line with prior predicted benefits calculated from a large body of observational evidence.[33,49,50]

3. Dose-response gradient: Greater adherence to the MedDiet showed an increased protection in a linear-trend fashion. Each additional 2-point increment in baseline adherence to the 0 to 9 MedDiet score was associated with a monotonic 11% relative reduction in CVD.[50]

4. Consistency: The 5 most comprehensive and recent meta-analyses published between 2014 and 2018 systematically evaluated this principle of consistency and concluded in favor of a strong and consistent cardiovascular protection by the MedDiet.[33,49–52,87] Also, 6 additional prospective studies not included in any of these meta-analyses supported this notion.[41,124–128] In total, 45[11,22,23,35–39,41,60,66,67,71–73,78–80,83,84,88,97,102–104,108–115,117–121,124–129,153] reports of prospective studies were available, including 5 RCTs and 32 independent observational cohorts (some cohorts made several publications; Figure 4; Online Table I). The immense majority of these studies repeatedly found that a MedDiet was beneficial for cardiovascular health under quite a wide variety of circumstances, ruling out chance or confounding as an explanation for this association.

Furthermore, both measured and unmeasured potential confounding were rigorously discarded as alternative explanations in additional specific analyses conducted in the republished report of PREDIMED (please check the Online Appendix Table XXV of that report[11]). In several meta-analyses, the removal of one study at a time did not nullify the inverse association between MedDiet and cardiovascular events.

5. Biological plausibility: The MedDiet is associated with marked and consistent reductions in cardiovascular risk factors[154] and in levels of vascular inflammatory biomarkers.[7] The high fruit and vegetable intake contributes to its high antioxidant content and other pleiotropic benefits provided by the polyphenols and other bioactive molecules present in fruits, vegetables, EVOO, nuts, whole grains, and wine, in the context of a MedDiet. Additionally, it is known that food items and nutrients may have synergistic effects when they are consumed in combination.

6. Specificity: This criterion is probably one of the weakest among the list proposed by Hill, because many exposures, including the MedDiet, are well-known to be associated with multiple outcomes. However, in agreement with the antiatherogenic properties of the foods

typical of the MedDiet, closer adherence to the MedDiet appears to protect specifically against ischemic manifestations of CVD (MI, ischemic stroke, or peripheral artery disease[155]) but its effects were found null against hemorrhagic stroke with an RR of 1.01 (95% CI, 0.74–1.37).[49] In the PREDIMED trial, the protective effect was present against the composite CVD outcome (composed mainly of ischemic clinical manifestations), but it was absent for total mortality, an end point that was not specific, because it included any cause of death, regardless of its relationship with nutrition or atherosclerosis.

7. Coherence: The association between MedDiet adherence and better cardiovascular health fits well within the known facts of the natural history and biology of CVD, as demonstrated by the Lyon trial for secondary prevention.[82] Beneficial effects on surrogate markers of CV risk adds coherence to the epidemiological evidence that supports a protective effect of the MedDiet.

8. Experimental evidence: The availability of several randomized trials using not only intermediate marker, but hard clinical end points is a considerably strength of the MedDiet, that is not available for any other dietary pattern. In addition, a good number of mechanistic trials conducted in subsets of participants by the PREDIMED investigators (see https://www.predimed.es/publications.html) provide substantial analytical evidence supporting the biological bases for the effect of a MedDiet in lowering the risk of CVD events.

9. Analogy: Other high-quality dietary patterns, such as the dietary approaches to stop hypertension (DASH) or the Alternative Healthy Eating Index, have also been associated with reduced incidence of CVD events. However, lack of analogy should not be considered as a criterion against causality. In fact, first-level evidence for the cardioprotective effect of the MedDiet, as collected and analyzed in PREDIMED and other trials, is not available for any other dietary pattern.

High Nutritional Quality of the MedDiet Adds Biological Plausibility to These Findings

Nutrition profiling and nutritional quality are topics of considerable current interest.[156] In this context, an additional element that adds biological plausibility to the findings of cohort studies and RCTs is a body of evidence supporting the high nutritional quality of the MedDiet (ie, it is a nutrient-dense option) over alternative actual dietary patterns which tend to be energy-rich but nutrient-poor.

Maillot et al[157] modeled nutritionally adequate diets to simultaneously met the requirements for a whole set of nutrient goals (proteins, fiber, essential fatty acids, 10 vitamins, 9 minerals, sodium, saturated fatty acids, and free sugars) while deviating the least from the observed diet in terms of food content. They found a strong consistency in the dietary changes needed to fulfill the constraints, and the greatest increases were seen for unsalted nuts, whole grains, legumes, fruit, fish/shellfish, and vegetables. They concluded that regardless of the different scenarios that they assumed, those foods which are typical of the MedDiet are needed to reach overall nutrient adequacy.

In the Mediterranean SUN cohort, a closer adherence to the MedDiet was reported to be strongly associated with a lower risk of failing to meet the goals for nutrient adequacy.[158,159] As adherence to the MedDiet increased, the probability of not fulfilling the micronutrient goals sharply decreased.[159] This finding was replicated in other studies.[160] In another study, the SUN cohort investigators evaluated the intakes of Zn, I, Se, Fe, Ca, K, P, Mg, Cr and vitamins B1, B2, B3, B6, B12, C, A, D, E, and folic acid. The probability of intake adequacy was evaluated using the estimated average requirement cutoff point approach and the probabilistic approach. Logistic regression analysis was used to assess the nutritional adequacy according to adherence to the MedDiet, evaluated the intakes of Zn, I, Se, Fe, Ca, K, P, Mg, Cr and vitamins B1, B2, B3, B6, B12, C, A, D, E, and folic acid. The results were similar showing a strong inverse association between adherence to the MedDiet and overall nutritional adequacy.[159] These results were replicated also in the PREDIMED cohort.[161] Therefore, it seems very likely that the overall better nutritional quality of the MedDietary pattern may be able to bring about a substantial reduction in the risk of atherosclerotic-ischemic events, which are known to be related to biochemical disorders caused by suboptimal intakes of several micronutrients.[162,163]

Concordance Between Cohorts and Trials

The findings of large observational cohort studies with good control for confounding are found to be replicated by the results of the 2 major trials (Lyon and PREDIMED). Such a strong consistency between large and well-conducted observational prospective cohorts and experimental studies is not available for any other dietary pattern. In addition to these 2 trials, there is another trial, the GOSPEL (Global Secondary Prevention Strategies to Limit Event Recurrence After Myocardial Infarction) study. GOSPEL was a multicenter, randomized secondary prevention trial in survivors of an MI who were on cardiac rehabilitation, that compared a long-term, reinforced, multifactorial educational, and behavioral intervention with usual care.[121] The intervention program where 1620 patients were allocated included the adoption of a healthy MedDiet together with smoking cessation, promotion of physical activity, and addressing conventional cardiovascular risk factors. The control group (n=1621) received usual care. At baseline, the scores of adherence to the MedDiet were equal in both groups. At 6 months, the score increased by 18% in the intervention group and by 14% in the usual care group, with modest but statistically significant differences between both. This difference in dietary habits between the 2 groups was maintained throughout the 3-year average duration of the study. The primary end point included cardiovascular mortality, nonfatal MI, and nonfatal stroke, but also several softer events not included in the PREDIMED trial (hospitalization for angina pectoris, heart failure, or urgent revascularization procedures). The intensive intervention nonsignificantly decreased the absolute risk by 2.1% (from 18.2% to 16.1%) of this combined primary cardiovascular end point (in total, 556 events). The *relative* reduction was 12% (RR, 0.88; 95% CI, 0.74–1.04; *P*=0.12) compared with usual care. However, it significantly decreased cardiovascular mortality plus nonfatal MI and stroke (in total 129 events; RR, 0.67; 95% CI, 0.47–0.95; *P*=0.02) with respect to usual care (RR reduction, 33%). However, the specific effect of the modest dietary contrast achieved between the

intervention and control groups cannot be separated from the overall intervention program that included many other aspects. In any case, given the small magnitude of the dietary contrast and the probably nonspecific nature of the primary end point of the GOSPEL trial, the results for the combination of MI, stroke, and cardiovascular death are more specific and they go in agreement with their expected direction.

Robustness of the Findings of the PREDIMED Trial in a Wide Variety of Sensitivity and Ancillary Analyses

The greatest challenge in the PREDIMED trial was to obtain an effective change in the overall dietary pattern of 7447 participants. A validated 14-item score was used to appraise the achieved changes in the overall food pattern.[25] The intervention was based on quarterly individual interviews and quarterly group sessions (with <20 participants per group) run by trained dietitians, provision of information on typical Mediterranean foods and dishes, shopping lists, weekly menus, cook recipes, and gifts of EVOO and mixed nuts. Figure 5 shows the contrast between the baseline 14-item score (all participants) and this score after 1 year of intervention in the 2 groups allocated to MedDiets (merged together) and in the control group. The intervention was successful in attaining changes in many aspects of the overall food pattern and this is the main strength of PREDIMED.

The methodological issues in the PREDIMED trial consisted in departures from the individual randomization protocol recently reported in detail elsewhere.[11] Briefly, 425 participants, members of the same household of a previous participant were directly allocated during all trial duration to the same group as their previously randomized relative. In addition, 441 individual participants and 26 participant members of the same household from 1 of the 11 recruiting centers were allocated by clusters (clinics) instead of using individual randomization. These issues were addressed by additionally adjusting for propensity scores that used 30 variables to estimate the probability that a participant would be allocated to each of the 3 intervention groups and with the use of robust variance estimators to account for intracluster correlations.[11] The results and conclusions remained intact after accounting for these small and partial departures from individual randomization in a subset of the trial. As a sensitivity analysis, a new per-protocol (adherence-adjusted) analysis was conducted and it found a hazard ratio for the primary cardiovascular end point of 0.42 (95% CI, 0.24–0.63) for the MedDiet as compared with the control diet. Further sensitivity analyses excluding participants not individually randomized provided a very convincing picture, and kept the same message: the intervention caused a 30% reduction in the composite cardiovascular end point of MI, stroke, or cardiovascular death (the point estimates of the hazard ratios in all these intention-to-treat sensitivity analyses ranged from 0.64 to 0.72, and their upper 95% confidence limits from 0.88 to 0.97).

There might be some concerns because of the possibility of unmeasured confounding. In this regard, the observed hazard ratio of 0.70 could be explained away by an unmeasured/unknown confounder that was associated with both the intervention group and the outcome by a risk ratio of 2.21, but weaker confounding could not do so (E value=2.21 for

Figure 5. Adherence to the Mediterranean diet (MedDiet) in participants from the PREDIMED (Prevención con Dieta Mediterránea) trial at baseline and after 1-y follow-up.

the point estimate and 1.5 for the upper limit of the CI).[164] In addition, it is important to not forget that when subjects with potential issues about departures from individual randomization were excluded, the protective effect was not attenuated, in fact, it slightly increased.

Biological Plausibility for the Effects of Polyphenol-Rich Foods in the MedDiet

A substudy of PREDIMED including 1139 subjects measured total urinary polyphenol excretion at baseline and after 1-year intervention and categorized participants according to thirds of their changes in urinary total polyphenol excretion. Participants in the highest tertile of changes in urinary total polyphenol excretion showed significantly lower plasma

levels of inflammatory biomarkers including VCAM (vascular cell adhesion molecule)-1, ICAM (intercellular adhesion molecule)-1, IL (interleukin)-6, TNF (tumor necrosis factor)-α, and monocyte chemotactic protein-1 as compared with those in the lowest tertile. A significant inverse correlation existed between urinary total polyphenol excretion and the plasma concentration of VCAM-1. Systolic and diastolic blood pressure decreased and plasma HDL-C increased in parallel with increasing urinary total polyphenol excretion.[46] This finding suggests a dose-dependent anti-inflammatory effect of polyphenols within the amounts that they were consumed in participants allocated to receive quarterly education and advice on the MedDiet during 1 year. Moreover, in the PREDIMED trial, polyphenol intake, as derived from food-frequency questionnaires, was inversely associated with the incidence of cardiovascular events,[165] blood pressure,[166] and total mortality.[167]

The polyphenol-rich MedDiet has also been found to influence the expression of key genes involved in vascular inflammation, foam cell formation, and thrombosis. In addition, specific polyphenols should not be viewed in isolation, but as one of many cofactors in synergistic action with other beneficial elements included in the overall MedDiet pattern. For example, a substudy of PREDIMED demonstrated that the dietary intervention was able to actively modulate the expression of proatherothrombotic genes.[168]

In plasma metabolomic studies, the MedDiet was able to attenuate the harmful cardiovascular effects of branched-chain amino acids,[169] ceramides,[170] and adverse metabolites in the tryptophan-kynurenine pathway.[171] Many other mechanistic studies support that the amounts of polyphenols usually present in the traditional MedDiet are enough as to bring about substantial changes in metabolic pathways which play a pivotal role in cardiovascular health.[172]

Further Experimental Evidence Beyond the PREDIMED and Lyon Trials

Dinu et al[52] in their umbrella meta-analysis of the health effects of the MedDiet assessed 16 different meta-analyses of RCTs on the effects of the MedDiet on different outcomes. They reported that 26 evaluations of cardiovascular outcomes were included in these meta-analyses. All point estimates from these meta-analyses were in the direction towards a benefit of the MedDiet for cardiovascular health, and most of these meta-analytical estimates from RCTs showed statistically significant results. Dinu et al[52] repeated the same methodology than Huedo-Medina et al[32] had used earlier for the evaluation of the quality of meta-analyses and applied the AMSTAR-MedSD tool used by Huedo-Medina. Dinu et al[52] in their updated evaluation obtained better results since they concluded that "all the investigated meta-analyses achieved a medium-to-high quality score, so suggesting that current meta-analyses evaluating the effects of the MedDiet on health status partially or almost fully comply with methodologic quality standards".

The question of potential publication bias was explicitly addressed by Rosato et al.[49] They found suggestion of small-study effects, but when they stratified the results according to number of cases of CHD, they found an RR of 0.71 (95% CI, 0.64–0.79) and 0.60 (95% CI, 0.48–0.76), respectively, for studies including >600 cases compared with smaller studies.

Similarly, for stroke, the RRs were 0.82 (95% CI, 0.72–0.94) and 0.52 (95% CI, 0.26–1.03) for studies including >300 cases compared with smaller studies. This finding of inverse association both in large and small studies does not indicate that publication bias may provide an alternative noncausal explanation of these findings.

The 95% prediction intervals in meta-analyses go beyond CIs because they also account for between-study heterogeneity and provide a credible range to be 95% confident that the effect reported by a new imaginary study examining the same association will lie within that range.[173] Galbete et al[33] examined the 95% prediction interval for the association of the MedDiet with chronic disease risk. They reported that 95% prediction intervals excluded the null value for the associations with CVD incidence, or mortality, CHD, and stroke. Therefore, there is reassuring evidence for these associations.

We acknowledge that both the Lyon trial and PREDIMED were conducted in Mediterranean areas, where the expected compliance with the MedDiet is likely to be higher. However, many of the studies shown in Figure 4 were conducted outside the Mediterranean basin and they found excellent results for this dietary pattern. Therefore, though there is a need to replicate the findings of PREDIMED in other Western areas, the MedDiet seems to have also a high potential for transferability.[50]

Major Sources of Information Had No Conflict of Interest With the Food Industry

In the PREDIMED trial, which remains as the most significant contribution to the scientific literature on a traditional MedDiet, food companies only donated the food items, but the trial was funded by an independent public agency (Instituto de Salud Carlos III, ie, the Spanish National Institutes of Health) without any commercial interest whatsoever. The umbrella meta-analysis by Galbete et al[33] was funded by the German Federal Ministry of Education and Research. The authors of the main recent meta-analyses,[49–52,87] reported no conflicts of interest with the food industry. The studies included in these meta-analyses that contributed with a higher amount of person-years (Nurses Health Study,[23] EPIC study,[22,111] and the National Institutes of Health-American Association of Retired Persons,[60] were publicly funded.

Conclusions

We have shown here that there is a large, strong, plausible, and consistent body of available prospective evidence to support the benefits of the MedDiet on cardiovascular health. Moreover, in the era of assessing overall food patterns, no other dietary pattern has undergone such a comprehensive, repeated, and international assessment of its cardiovascular effects. The MedDiet has successfully passed all the needed tests and it approaches the gold standard for cardiovascular health.

The MedDiet can be adapted to many different geographic settings by tailoring it to individual characteristics such as food and cultural preferences and health conditions. Promotion of the MedDiet requires changes in the food environment, the food systems, and public health policies to improve overall diet quality of individuals, communities, and populations.

Acknowledgments

Sources of Funding

Disclosures

None.

References

1. Lloyd-Jones DM, Hong Y, Labarthe D, et al; American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. *Circulation*. 2010;121:586–613. doi: 10.1161/CIRCULATIONAHA.109.192703

2. Hu FB. Globalization of food patterns and cardiovascular disease risk. *Circulation*. 2008;118:1913–1914. doi: 10.1161/CIRCULATIONAHA.108.808493

3. Tapsell LC, Neale EP, Satija A, Hu FB. Foods, nutrients, and dietary patterns: interconnections and implications for dietary guidelines. *Adv Nutr*. 2016;7:445–454. doi: 10.3945/an.115.011718

4. Hu FB. Dietary pattern analysis: a new direction in nutritional epidemiology. *Curr Opin Lipidol*. 2002;13:3–9.

5. da Silva R, Bach-Faig A, Raidó Quintana B, Buckland G, Vaz de Almeida MD, Serra-Majem L. Worldwide variation of adherence to the Mediterranean diet, in 1961-1965 and 2000-2003. *Public Health Nutr*. 2009;12:1676–1684. doi: 10.1017/S1368980009990541

6. Trichopoulou A, Lagiou P. Healthy traditional Mediterranean diet: an expression of culture, history, and lifestyle. *Nutr Rev*. 1997;55:383–389.

7. Schwingshackl L, Hoffmann G. Mediterranean dietary pattern, inflammation and endothelial function: a systematic review and meta-analysis of intervention trials. *Nutr Metab Cardiovasc Dis*. 2014;24:929–939. doi: 10.1016/j.numecd.2014.03.003

8. Guasch-Ferré M, Hu FB, Martínez-González MA, et al. Olive oil intake and risk of cardiovascular disease and mortality in the PREDIMED Study. *BMC Med*. 2014;12:78. doi: 10.1186/1741-7015-12-78

9. Guo X, Tresserra-Rimbau A, Estruch R, Martínez-González MA, Medina-Remón A, Castañer O, Corella D, Salas-Salvadó J, Lamuela-Raventós RM. Effects of polyphenol, measured by a biomarker of total polyphenols in urine, on cardiovascular risk factors after a long-term follow-up in the PREDIMED study. *Oxid Med Cell Longev*. 2016;2016:2572606. doi: 10.1155/2016/2572606

10. Beauchamp GK, Keast RS, Morel D, Lin J, Pika J, Han Q, Lee CH, Smith AB, Breslin PA. Phytochemistry: ibuprofen-like activity in extra-virgin olive oil. *Nature*. 2005;437:45–46. doi: 10.1038/437045a

11. Estruch R, Ros E, Salas-Salvadó J, et al; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. *N Engl J Med*. 2018;378:e34. doi: 10.1056/NEJMoa1800389

12. Ferro-Luzzi A, Sette S. The Mediterranean diet: an attempt to define its present and past composition. *Eur J Clin Nutr*. 1989;43(suppl 2):13–29.

13. Nestle M. Mediterranean diets: historical and research overview. *Am J Clin Nutr*. 1995;61:1313S–1320S. doi: 10.1093/ajcn/61.6.1313S

14. Haber B. The Mediterranean diet: a view from history. *Am J Clin Nutr*. 1997;66:1053S–1057S. doi: 10.1093/ajcn/66.4.1053S

15. Lesser LI, Ebbeling CB, Goozner M, Wypij D, Ludwig DS. Relationship between funding source and conclusion among nutrition-related scientific articles. *PLoS Med*. 2007;4:e5. doi: 10.1371/journal.pmed.0040005

16. Rowe S, Alexander N, Clydesdale FM, et al. Funding food science and nutrition research: financial conflicts and scientific integrity. *Am J Clin Nutr*. 2009;89:1285–1291. doi: 10.3945/ajcn.2009.27604

17. Litman EA, Gortmaker SL, Ebbeling CB, Ludwig DS. Source of bias in sugar-sweetened beverage research: a systematic review. *Public Health Nutr*. 2018;21:2345–2350. doi: 10.1017/S1368980018000575

18. Smith R. Are some diets "mass murder"? *BMJ*. 2014;349:g7654. doi: 10.1136/bmj.g7654

19. Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. *Circulation*. 2016;133:187–225. doi: 10.1161/CIRCULATIONAHA.115.018585

20. Yu D, Shu XO, Li H, Xiang YB, Yang G, Gao YT, Zheng W, Zhang X. Dietary carbohydrates, refined grains, glycemic load, and risk of coronary heart disease in Chinese adults. *Am J Epidemiol*. 2013;178:1542–1549. doi: 10.1093/aje/kwt178

21. Zazpe I, Santiago S, Gea A, Ruiz-Canela M, Carlos S, Bes-Rastrollo M, Martínez-González MA. Association between a dietary carbohydrate index and cardiovascular disease in the SUN (Seguimiento Universidad de Navarra) Project. *Nutr Metab Cardiovasc Dis*. 2016;26:1048–1056. doi: 10.1016/j.numecd.2016.07.002

22. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. *N Engl J Med*. 2003;348:2599–2608. doi: 10.1056/NEJMoa025039

23. Fung TT, Rexrode KM, Mantzoros CS, Manson JE, Willett WC, Hu FB. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. *Circulation*. 2009;119:1093–1100. doi: 10.1161/CIRCULATIONAHA.108.816736

24. Panagiotakos DB, Pitsavos C, Stefanadis C. Dietary patterns: a Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk. *Nutr Metab Cardiovasc Dis*. 2006;16:559–568. doi: 10.1016/j.numecd.2005.08.006

25. Schröder H, Fitó M, Estruch R, et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. *J Nutr*. 2011;141:1140–1145. doi: 10.3945/jn.110.135566

26. GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2018;392:1015–1035. doi: 10.1016/S0140-6736(18)31310-2

27. Burton R, Sheron N. No level of alcohol consumption improves health. *Lancet*. 2018;392:987–988. doi: 10.1016/S0140-6736(18)31571-X

28. Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, Negri E, Straif K, Romieu I, La Vecchia C, Boffetta P, Jenab M. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. *Ann Oncol*. 2011;22:1958–1972. doi: 10.1093/annonc/mdq653

29. Buckland G, Travier N, Cottet V, et al. Adherence to the mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study. *Int J Cancer*. 2013;132:2918–2927. doi: 10.1002/ijc.27958

30. Gijsbers L, Ding EL, Malik VS, de Goede J, Geleijnse JM, Soedamah-Muthu SS. Consumption of dairy foods and diabetes incidence: a dose-response meta-analysis of observational studies. *Am J Clin Nutr*. 2016;103:1111–1124. doi: 10.3945/ajcn.115.123216

31. Hu D, Huang J, Wang Y, Zhang D, Qu Y. Dairy foods and risk of stroke: a meta-analysis of prospective cohort studies. *Nutr Metab Cardiovasc Dis*. 2014;24:460–469. doi: 10.1016/j.numecd.2013.12.006

32. Huedo-Medina TB, Garcia M, Bihuniak JD, Kenny A, Kerstetter J. Methodologic quality of meta-analyses and systematic reviews on the Mediterranean diet and cardiovascular disease outcomes: a review. *Am J Clin Nutr*. 2016;103:841–850. doi: 10.3945/ajcn.115.112771

33. Galbete C, Schwingshackl L, Schwedhelm C, Boeing H, Schulze MB. Evaluating Mediterranean diet and risk of chronic disease in cohort studies: an umbrella review of meta-analyses. *Eur J Epidemiol*. 2018;33:909–931. doi: 10.1007/s10654-018-0427-3

34. Tognon G, Nilsson LM, Lissner L, Johansson I, Hallmans G, Lindahl B, Winkvist A. The Mediterranean diet score and mortality are inversely associated in adults living in the subarctic region. *J Nutr*. 2012;142:1547–1553. doi: 10.3945/jn.112.160499

35. Knoops KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti A, van Staveren WA. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. *JAMA*. 2004;292:1433–1439. doi: 10.1001/jama.292.12.1433

36. Trichopoulou A, Kouris-Blazos A, Wahlqvist ML, Gnardellis C, Lagiou P, Polychronopoulos E, Vassilakou T, Lipworth L, Trichopoulos D. Diet and overall survival in elderly people. *BMJ*. 1995;311:1457–1460.

37. Sjögren P, Becker W, Warensjö E, Olsson E, Byberg L, Gustafsson IB, Karlström B, Cederholm T. Mediterranean and carbohydrate-restricted

diets and mortality among elderly men: a cohort study in Sweden. *Am J Clin Nutr*. 2010;92:967–974. doi: 10.3945/ajcn.2010.29345

38. Tognon G, Lissner L, Sæbye D, Walker KZ, Heitmann BL. The Mediterranean diet in relation to mortality and CVD: a Danish cohort study. *Br J Nutr*. 2014;111:151–159. doi: 10.1017/S0007114513001931

39. Chrysohoou C, Panagiotakos DB, Aggelopoulos P, Kastorini CM, Kehagia I, Pitsavos C, Stefanadis C. The Mediterranean diet contributes to the preservation of left ventricular systolic function and to the long-term favorable prognosis of patients who have had an acute coronary event. *Am J Clin Nutr*. 2010;92:47–54. doi: 10.3945/ajcn.2009.28982

40. Martínez-González MA, Estruch R, Corella D, Ros E, Fitó M, Schwingshackl L, Salas-Salvadó J. Effects on health outcomes of a Mediterranean diet with no restriction on fat intake. *Ann Intern Med*. 2017;166:378. doi: 10.7326/L16-0589

41. Trichopoulou A, Bamia C, Trichopoulos D. Mediterranean diet and survival among patients with coronary heart disease in Greece. *Arch Intern Med*. 2005;165:929–935. doi: 10.1001/archinte.165.8.929

42. Covas MI, Nyyssönen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, Gaddi A, de la Torre R, Mursu J, Bäumler H, Nascetti S, Salonen JT, Fitó M, Virtanen J, Marrugat J; EUROLIVE Study Group. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. *Ann Intern Med*. 2006;145:333–341. doi: 10.7326/0003-4819-145-5-200609050-00006

43. Crespo MC, Tomé-Carneiro J, Dávalos A, Visioli F. Pharma-nutritional properties of olive oil phenols. Transfer of new findings to human nutrition. *Foods*. 2018;7:E90. doi: 10.3390/foods7060090

44. Hernández-Ruiz A, García-Villanova B, Guerra-Hernández E, Amiano P, Sánchez MJ, Dorronsoro M, Molina-Montes E. Comparison of the Dietary Antioxidant Profiles of 21 a priori Defined Mediterranean Diet Indexes. *J Acad Nutr Diet*. 2018;118:2254.e8–2268.e8. doi: 10.1016/j.jand.2018.01.006

45. Zamora-Ros R, Knaze V, Luján-Barroso L, et al. Differences in dietary intakes, food sources and determinants of total flavonoids between Mediterranean and non-Mediterranean countries participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Br J Nutr*. 2013;109:1498–1507. doi: 10.1017/S0007114512003273

46. Medina-Remón A, Casas R, Tresserra-Rimbau A, Ros E, Martínez-González MA, Fitó M, Corella D, Salas-Salvadó J, Lamuela-Raventos RM, Estruch R; PREDIMED Study Investigators. Polyphenol intake from a Mediterranean diet decreases inflammatory biomarkers related to atherosclerosis: a substudy of the PREDIMED trial. *Br J Clin Pharmacol*. 2017;83:114–128. doi: 10.1111/bcp.12986

47. Romaguera D, Norat T, Vergnaud AC, et al. Mediterranean dietary patterns and prospective weight change in participants of the EPIC-PANACEA project. *Am J Clin Nutr*. 2010;92:912–921. doi: 10.3945/ajcn.2010.29482

48. Martínez-González MA, Salas-Salvadó J, Estruch R, Corella D, Fitó M, Ros E; PREDIMED INVESTIGATORS. Benefits of the Mediterranean diet: insights from the PREDIMED Study. *Prog Cardiovasc Dis*. 2015;58:50–60. doi: 10.1016/j.pcad.2015.04.003

49. Rosato V, Temple NJ, La Vecchia C, Castellan G, Tavani A, Guercio V. Mediterranean diet and cardiovascular disease: a systematic review and meta-analysis of observational studies [published online November 25, 2017]. *Eur J Nutr*. doi: 10.1007/s00394-017-1582-0. https://link.springer.com/article/10.1007%2Fs00394-017-1582-0.

50. Martínez-González MÁ, Hershey MS, Zazpe I, Trichopoulou A. Transferability of the Mediterranean diet to non-Mediterranean countries. What is and what is not the Mediterranean Diet. *Nutrients*. 2017;9:E1226. doi: 10.3390/nu9111226. Erratum in: *Nutrients*. 2018;10(7).

51. Grosso G, Marventano S, Yang J, Micek A, Pajak A, Scalfi L, Galvano F, Kales SN. A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: are individual components equal? *Crit Rev Food Sci Nutr*. 2017;57:3218–3232. doi: 10.1080/10408398.2015.1107021

52. Dinu M, Pagliai G, Casini A, Sofi F. Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials. *Eur J Clin Nutr*. 2018;72:30–43. doi: 10.1038/ejcn.2017.58

53. de Lorgeril M, Salen P. Mediterranean type of diet for the prevention of coronary heart disease. A global perspective from the seven countries study to the most recent dietary trials. *Int J Vitam Nutr Res*. 2001;71:166–172. doi: 10.1024/0300-9831.71.3.166

54. Panagiotakos DB, Pitsavos C, Polychronopoulos E, Chrysohoou C, Zampelas A, Trichopoulou A. Can a Mediterranean diet moderate the development and clinical progression of coronary heart disease? A systematic review. *Med Sci Monit*. 2004;10:RA193–RA198.

55. Serra-Majem L, Roman B, Estruch R. Scientific evidence of interventions using the Mediterranean diet: a systematic review. *Nutr Rev*. 2006;64:S27–S47.

56. Willett WC. The Mediterranean diet: science and practice. *Public Health Nutr*. 2006;9:105–110.

57. de Lorgeril M, Salen P. The Mediterranean diet: rationale and evidence for its benefit. *Curr Atheroscler Rep*. 2008;10:518–522.

58. Roman B, Carta L, Martínez-González MA, Serra-Majem L. Effectiveness of the Mediterranean diet in the elderly. *Clin Interv Aging*. 2008;3:97–109.

59. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. *BMJ*. 2008;337:a1344. doi: 10.1136/bmj.a1344

60. Mitrou PN, Kipnis V, Thiébaut AC, Reedy J, Subar AF, Wirfält E, Flood A, Mouw T, Hollenbeck AR, Leitzmann MF, Schatzkin A. Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. *Arch Intern Med*. 2007;167:2461–2468. doi: 10.1001/archinte.167.22.2461

61. Martinez-Gonzalez MA, Bes-Rastrollo M, Serra-Majem L, Lairon D, Estruch R, Trichopoulou A. Mediterranean food pattern and the primary prevention of chronic disease: recent developments. *Nutr Rev*. 2009;67(suppl 1):S111–S116. doi: 10.1111/j.1753-4887.2009.00172.x

62. Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. *Arch Intern Med*. 2009;169:659–669. doi: 10.1001/archinternmed.2009.38

63. Sofi F. The Mediterranean diet revisited: evidence of its effectiveness grows. *Curr Opin Cardiol*. 2009;24:442–446. doi: 10.1097/HCO.0b013e32832f056e

64. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. *Am J Clin Nutr*. 2010;92:1189–1196. doi: 10.3945/ajcn.2010.29673

65. Tyrovolas S, Panagiotakos DB. The role of Mediterranean type of diet on the development of cancer and cardiovascular disease, in the elderly: a systematic review. *Maturitas*. 2010;65:122–130. doi: 10.1016/j.maturitas.2009.07.003

66. Buckland G, González CA, Agudo A, et al. Adherence to the Mediterranean diet and risk of coronary heart disease in the Spanish EPIC Cohort Study. *Am J Epidemiol*. 2009;170:1518–1529. doi: 10.1093/aje/kwp282

67. Martínez-González MA, García-López M, Bes-Rastrollo M, Toledo E, Martínez-Lapiscina EH, Delgado-Rodriguez M, Vazquez Z, Benito S, Beunza JJ. Mediterranean diet and the incidence of cardiovascular disease: a Spanish cohort. *Nutr Metab Cardiovasc Dis*. 2011;21:237–244.

68. McKeown PP, Logan K, McKinley MC, Young IS, Woodside JV. Session 4: CVD, diabetes and cancer: evidence for the use of the Mediterranean diet in patients with CHD. *Proc Nutr Soc*. 2010;69:45–60. doi: 10.1017/S0029665109991856

69. Foroughi M, Akhavanzanjani M, Maghsoudi Z, Ghiasvand R, Khorvash F, Askari G. Stroke and nutrition: a review of studies. *Int J Prev Med*. 2013;4:S165–S179.

70. Psaltopoulou T, Sergentanis TN, Panagiotakos DB, Sergentanis IN, Kosti R, Scarmeas N. Mediterranean diet, stroke, cognitive impairment, and depression: a meta-analysis. *Ann Neurol*. 2013;74:580–591. doi: 10.1002/ana.23944

71. Agnoli C, Krogh V, Grioni S, Sieri S, Palli D, Masala G, Sacerdote C, Vineis P, Tumino R, Frasca G, Pala V, Berrino F, Chiodini P, Mattiello A, Panico S. A priori-defined dietary patterns are associated with reduced risk of stroke in a large Italian cohort. *J Nutr*. 2011;141:1552–1558. doi: 10.3945/jn.111.140061

72. Gardener H, Wright CB, Gu Y, Demmer RT, Boden-Albala B, Elkind MS, Sacco RL, Scarmeas N. Mediterranean-style diet and risk of ischemic stroke, myocardial infarction, and vascular death: the Northern Manhattan Study. *Am J Clin Nutr*. 2011;94:1458–1464. doi: 10.3945/ajcn.111.012799

73. Hoevenaar-Blom MP, Nooyens AC, Kromhout D, Spijkerman AM, Beulens JW, van der Schouw YT, Bueno-de-Mesquita B, Verschuren WM. Mediterranean style diet and 12-year incidence of cardiovascular diseases: the EPIC-NL cohort study. *PLoS One*. 2012;7:e45458. doi: 10.1371/journal.pone.0045458

74. Rees K, Hartley L, Flowers N, Clarke A, Hooper L, Thorogood M, Stranges S. 'Mediterranean' dietary pattern for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2013:CD009825.

75. de Lorgeril M. Mediterranean diet and cardiovascular disease: historical perspective and latest evidence. *Curr Atheroscler Rep*. 2013;15:370. doi: 10.1007/s11883-013-0370-4

76. Grosso G, Mistretta A, Frigiola A, Gruttadauria S, Biondi A, Basile F, Vitaglione P, D'Orazio N, Galvano F. Mediterranean diet and cardiovascular risk factors: a systematic review. *Crit Rev Food Sci Nutr.* 2014;54:593–610. doi: 10.1080/10408398.2011.596955

77. Kontogianni MD, Panagiotakos DB. Dietary patterns and stroke: a systematic review and re-meta-analysis. *Maturitas.* 2014;79:41–47. doi: 10.1016/j.maturitas.2014.06.014

78. Estruch R, Ros E, Salas-Salvadó J, et al; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med.* 2013;368:1279–1290. doi: 10.1056/NEJMoa1200303

79. Misirli G, Benetou V, Lagiou P, Bamia C, Trichopoulos D, Trichopoulou A. Relation of the traditional Mediterranean diet to cerebrovascular disease in a Mediterranean population. *Am J Epidemiol.* 2012;176:1185–1192. doi: 10.1093/aje/kws205

80. Chan R, Chan D, Woo J. The association of a priori and a posterior dietary patterns with the risk of incident stroke in Chinese older people in Hong Kong. *J Nutr Health Aging.* 2013;17:866–874. doi: 10.1007/s12603-013-0334-y

81. Martinez-Gonzalez MA, Bes-Rastrollo M. Dietary patterns, Mediterranean diet, and cardiovascular disease. *Curr Opin Lipidol.* 2014;25:20–26. doi: 10.1097/MOL.0000000000000044

82. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation.* 1999;99:779–785.

83. Dilis V, Katsoulis M, Lagiou P, Trichopoulos D, Naska A, Trichopoulou A. Mediterranean diet and CHD: the Greek European Prospective Investigation into Cancer and Nutrition cohort. *Br J Nutr.* 2012;108:699–709. doi: 10.1017/S0007114512001821

84. Menotti A, Alberti-Fidanza A, Fidanza F. The association of the Mediterranean Adequacy Index with fatal coronary events in an Italian middle-aged male population followed for 40 years. *Nutr Metab Cardiovasc Dis.* 2012;22:369–375. doi: 10.1016/j.numecd.2010.08.002

85. Martínez-González MA, García-López M, Bes-Rastrollo M, Toledo E, Martínez-Lapiscina EH, Delgado-Rodriguez M, Vazquez Z, Benito S, Beunza JJ. Mediterranean diet and the incidence of cardiovascular disease: a Spanish cohort. *Nutr Metab Cardiovasc Dis.* 2011;21:237–44.

86. Ros E, Martínez-González MA, Estruch R, Salas-Salvadó J, Fitó M, Martínez JA, Corella D. Mediterranean diet and cardiovascular health: teachings of the PREDIMED study. *Adv Nutr.* 2014;5:330S–336S. doi: 10.3945/an.113.005389

87. Sofi F, Macchi C, Abbate R, Gensini GF, Casini A. Mediterranean diet and health status: an updated meta-analysis and a proposal for a literature-based adherence score. *Public Health Nutr.* 2014;17:2769–2782. doi: 10.1017/S1368980013003169

88. Buckland G, Agudo A, Travier N, et al. Adherence to the Mediterranean diet reduces mortality in the Spanish cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Spain). *Br J Nutr.* 2011;106:1581–1591. doi: 10.1017/S0007114511002078

89. Buckland G, Agudo A, Luján L, et al. Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study. *Am J Clin Nutr.* 2010;91:381–390. doi: 10.3945/ajcn.2009.28209

90. Trichopoulou A, Martínez-González MA, Tong TY, Forouhi NG, Khandelwal S, Prabhakaran D, Mozaffarian D, de Lorgeril M. Definitions and potential health benefits of the Mediterranean diet: views from experts around the world. *BMC Med.* 2014;12:112. doi: 10.1186/1741-7015-12-112

91. Whayne TF Jr. Ischemic heart disease and the Mediterranean diet. *Curr Cardiol Rep.* 2014;16:491. doi: 10.1007/s11886-014-0491-6

92. Sleiman D, Al-Badri MR, Azar ST. Effect of mediterranean diet in diabetes control and cardiovascular risk modification: a systematic review. *Front Public Health.* 2015;3:69. doi: 10.3389/fpubh.2015.00069

93. Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The Mediterranean diet, its components, and cardiovascular disease. *Am J Med.* 2015;128:229–238. doi: 10.1016/j.amjmed.2014.10.014

94. D'Alessandro A, De Pergola G. Mediterranean diet and cardiovascular disease: a critical evaluation of a priori dietary indexes. *Nutrients.* 2015;7:7863–7888. doi: 10.3390/nu7095367

95. Shen J, Wilmot KA, Ghasemzadeh N, Molloy DL, Burkman G, Mekonnen G, Gongora MC, Quyyumi AA, Sperling LS. Mediterranean dietary patterns and cardiovascular health. *Annu Rev Nutr.* 2015;35:425–449. doi: 10.1146/annurev-nutr-011215-025104

96. Liyanage T, Ninomiya T, Wang A, Neal B, Jun M, Wong MG, Jardine M, Hillis GS, Perkovic V. Effects of the Mediterranean diet on cardiovascular outcomes-A systematic review and meta-analysis. *PLoS One.* 2016;11:e0159252. doi: 10.1371/journal.pone.0159252

97. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. *Lancet.* 1994;343:1454–1459.

98. Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, Manor O, Pella D, Berry EM. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. *Lancet.* 2002;360:1455–1461. doi: 10.1016/S0140-6736(02)11472-3

99. Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, Zotos PC, Haboubi NA, Elwood PC. Lack of benefit of dietary advice to men with angina: results of a controlled trial. *Eur J Clin Nutr.* 2003;57:193–200. doi: 10.1038/sj.ejcn.1601539

100. Martinez-Gonzalez MA, Martin-Calvo N. Mediterranean diet and life expectancy; beyond olive oil, fruits, and vegetables. *Curr Opin Clin Nutr Metab Care.* 2016;19:401–407. doi: 10.1097/MCO.0000000000000316

101. Bloomfield HE, Koeller E, Greer N, MacDonald R, Kane R, Wilt TJ. Effects on health outcomes of a Mediterranean diet with no restriction on fat intake: a systematic review and meta-analysis. *Ann Intern Med.* 2016;165:491–500. doi: 10.7326/M16-0361

102. Bertoia ML, Triche EW, Michaud DS, Baylin A, Hogan JW, Neuhouser ML, Tinker LF, Van Horn L, Waring ME, Li W, Shikany JM, Eaton CB. Mediterranean and dietary approaches to stop hypertension dietary patterns and risk of sudden cardiac death in postmenopausal women. *Am J Clin Nutr.* 2014;99:344–351. doi: 10.3945/ajcn.112.056135

103. Tektonidis TG, Åkesson A, Gigante B, Wolk A, Larsson SC. A Mediterranean diet and risk of myocardial infarction, heart failure and stroke: a population-based cohort study. *Atherosclerosis.* 2015;243:93–98. doi: 10.1016/j.atherosclerosis.2015.08.039

104. Sotos-Prieto M, Bhupathiraju SN, Mattei J, Fung TT, Li Y, Pan A, Willett WC, Rimm EB, Hu FB. Changes in diet quality scores and risk of cardiovascular disease among US men and women. *Circulation.* 2015;132:2212–2219. doi: 10.1161/CIRCULATIONAHA.115.017158

105. Turati F, Pelucchi C, Galeone C, Praud D, Tavani A, La Vecchia C. Mediterranean diet and non-fatal acute myocardial infarction: a case-control study from Italy. *Public Health Nutr.* 2015;18:713–720. doi: 10.1017/S1368980014000858

106. Martínez-González MA, Fernández-Jarne E, Serrano-Martínez M, Marti A, Martinez JA, Martín-Moreno JM. Mediterranean diet and reduction in the risk of a first acute myocardial infarction: an operational healthy dietary score. *Eur J Nutr.* 2002;41:153–160. doi: 10.1007/s00394-002-0370-6

107. Yau WY, Hankey GJ. Which dietary and lifestyle behaviours may be important in the aetiology (and prevention) of stroke? *J Clin Neurosci.* 2011;18:76–80. doi: 10.1016/j.jocn.2010.05.014

108. Tsivgoulis G, Psaltopoulou T, Wadley VG, Alexandrov AV, Howard G, Unverzagt FW, Moy C, Howard VJ, Kissela B, Judd SE. Adherence to a Mediterranean diet and prediction of incident stroke. *Stroke.* 2015;46:780–785. doi: 10.1161/STROKEAHA.114.007894

109. Reedy J, Krebs-Smith SM, Miller PE, Liese AD, Kahle LL, Park Y, Subar AF. Higher diet quality is associated with decreased risk of all-cause, cardiovascular disease, and cancer mortality among older adults. *J Nutr.* 2014;144:881–889. doi: 10.3945/jn.113.189407

110. George SM, Ballard-Barbash R, Manson JE, Reedy J, Shikany JM, Subar AF, Tinker LF, Vitolins M, Neuhouser ML. Comparing indices of diet quality with chronic disease mortality risk in postmenopausal women in the Women's Health Initiative Observational Study: evidence to inform national dietary guidance. *Am J Epidemiol.* 2014;180:616–625. doi: 10.1093/aje/kwu173

111. Tong TY, Wareham NJ, Khaw KT, Imamura F, Forouhi NG. Prospective association of the Mediterranean diet with cardiovascular disease incidence and mortality and its population impact in a non-Mediterranean population: the EPIC-Norfolk study. *BMC Med.* 2016;14:135. doi: 10.1186/s12916-016-0677-4

112. Bellavia A, Tektonidis TG, Orsini N, Wolk A, Larsson SC. Quantifying the benefits of Mediterranean diet in terms of survival. *Eur J Epidemiol.* 2016;31:527–530. doi: 10.1007/s10654-016-0127-9

113. Panagiotakos DB, Georgousopoulou EN, Pitsavos C, Chrysohoou C, Skoumas I, Pitaraki E, Georgiopoulos GA, Ntertimani M, Christou A, Stefanadis C; ATTICA Study Group. Exploring the path of Mediterranean diet on 10-year incidence of cardiovascular disease: the ATTICA study (2002-2012). *Nutr Metab Cardiovasc Dis.* 2015;25:327–335. doi: 10.1016/j.numecd.2014.09.006

114. Bo S, Ponzo V, Goitre I, Fadda M, Pezzana A, Beccuti G, Gambino R, Cassader M, Soldati L, Broglio F. Predictive role of the Mediterranean

diet on mortality in individuals at low cardiovascular risk: a 12-year fol-low-up population-based cohort study. *J Transl Med*. 2016;14:91. doi: 10.1186/s12967-016-0851-7

115. Stefler D, Malyutina S, Kubinova R, Pajak A, Peasey A, Pikhart H, Brunner EJ, Bobak M. Mediterranean diet score and total and cardio-vascular mortality in Eastern Europe: the HAPIEE study. *Eur J Nutr*. 2017;56:421–429. doi: 10.1007/s00394-015-1092-x

116. Tektonidis TG, Åkesson A, Gigante B, Wolk A, Larsson SC. Adherence to a Mediterranean diet is associated with reduced risk of heart failure in men. *Eur J Heart Fail*. 2016;18:253–259. doi: 10.1002/ejhf.481

117. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas I, Stefanadis C; ATTICA Study. Five-year incidence of cardiovascular disease and its predictors in Greece: the ATTICA study. *Vasc Med*. 2008;13:113–121. doi: 10.1177/1358863x07087731

118. Hoevenaar-Blom MP, Spijkerman AM, Boshuizen HC, Boer JM, Kromhout D, Verschuren WM. Effect of using repeated measurements of a Mediterranean style diet on the strength of the association with cardi-ovascular disease during 12 years: the Doetinchem Cohort Study. *Eur J Nutr*. 2014;53:1209–1215. doi: 10.1007/s00394-013-0621-8

119. Hodge AM, English DR, Itsiopoulos C, O'Dea K, Giles GG. Does a Mediterranean diet reduce the mortality risk associated with diabetes: evidence from the Melbourne Collaborative Cohort Study. *Nutr Metab Cardiovasc Dis*. 2011;21:733–739. doi: 10.1016/j.numecd.2010.10.014

120. Lopez-Garcia E, Rodriguez-Artalejo F, Li TY, Fung TT, Li S, Willett WC, Rimm EB, Hu FB. The Mediterranean-style dietary pattern and mortality among men and women with cardiovascular disease. *Am J Clin Nutr*. 2014;99:172–180. doi: 10.3945/ajcn.113.068106

121. Giannuzzi P, Temporelli PL, Marchioli R, Maggioni AP, Balestroni G, Ceci V, Chieffo C, Gattone M, Griffo R, Schweiger C, Tavazzi L, Urbinati S, Valagussa F, Vanuzzo D; GOSPEL Investigators. Global sec-ondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized con-trolled trial from the Italian Cardiac Rehabilitation Network. *Arch Intern Med*. 2008;168:2194–2204. doi: 10.1001/archinte.168.20.2194

122. Martinez-Lacoba R, Pardo-Garcia I, Amo-Saus E, Escribano-Sotos F. Mediterranean diet and health outcomes: a systematic meta-review. *Eur J Public Health*. 2018;28:955–961. doi: 10.1093/eurpub/cky113

123. Salas-Salvadó J, Becerra-Tomás N, García-Gavilán JF, Bulló M, Barrubés L. Mediterranean diet and cardiovascular disease preven-tion: what do we know? *Prog Cardiovasc Dis*. 2018;61:62–67. doi: 10.1016/j.pcad.2018.04.006

124. Guallar-Castillón P, Rodríguez-Artalejo F, Tormo MJ, et al. Major die-tary patterns and risk of coronary heart disease in middle-aged persons from a Mediterranean country: the EPIC-Spain cohort study. *Nutr Metab Cardiovasc Dis*. 2012;22:192–199. doi: 10.1016/j.numecd.2010.06.004

125. Scarmeas N, Luchsinger JA, Stern Y, Gu Y, He J, DeCarli C, Brown T, Brickman AM. Mediterranean diet and magnetic resonance imaging-assessed cerebrovascular disease. *Ann Neurol*. 2011;69:257–268. doi: 10.1002/ana.22317

126. Hoevenaar-Blom MP, Spijkerman AM, Kromhout D, Verschuren WM. Sufficient sleep duration contributes to lower cardiovascular disease risk in addition to four traditional lifestyle factors: the MORGEN study. *Eur J Prev Cardiol*. 2014;21:1367–1375. doi: 10.1177/2047487313493057

127. Bonaccio M, Di Castelnuovo A, Costanzo S, Gialluisi A, Persichillo M, Cerletti C, Donati MB, de Gaetano G, Iacoviello L. Mediterranean diet and mortality in the elderly: a prospective cohort study and a meta-anal-ysis. *Br J Nutr*. 2018;30:1–14.

128. Paterson KE, Myint PK, Jennings A, Bain LKM, Lentjes MAH, Khaw KT, Welch AA. Mediterranean diet reduces risk of incident stroke in a population with varying cardiovascular disease risk profiles. *Stroke*. 2018;0:2415–2420.

129. Martínez-González MA, Guillén-Grima F, De Irala J, Ruíz-Canela M, Bes-Rastrollo M, Beunza JJ, López del Burgo C, Toledo E, Carlos S, Sánchez-Villegas A. The Mediterranean diet is associated with a re-duction in premature mortality among middle-aged adults. *J Nutr*. 2012;142:1672–1678. doi: 10.3945/jn.112.162891

130. Barnard ND, Willett WC, Ding EL. The misuse of meta-analysis in nutri-tion research. *JAMA*. 2017;318:1435–1436. doi: 10.1001/jama.2017.12083

131. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. *Lancet*. 1991;337:867–872.

132. De Lorgeril M, Salen P, Martin JL, Mamelle N, Monjaud I, Touboul P, Delaye J. Effect of a Mediterranean type of diet on the rate of cardio-vascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments. *J Am Coll Cardiol*. 1996;28:1103–1108. doi: 10.1016/S0735-1097(96)00280-X

133. Kris-Etherton P, Eckel RH, Howard BV, St Jeor S, Bazzarre TL; Nutrition Committee Population Science Committee and Clinical Science Committee of the American Heart Association. AHA Science Advisory: Lyon Diet Heart Study. Benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease. *Circulation*. 2001;103:1823–1825.

134. Bassler D, Briel M, Montori VM, et al; STOPIT-2 Study Group. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. *JAMA*. 2010;303:1180–1187. doi: 10.1001/jama.2010.310

135. Martínez-González MA, Sánchez-Villegas A. The emerging role of Mediterranean diets in cardiovascular epidemiology: monounsatu-rated fats, olive oil, red wine or the whole pattern? *Eur J Epidemiol*. 2004;19:9–13.

136. Horton R. Expression of concern: Indo-Mediterranean Diet Heart Study. *Lancet*. 2005;366:354–356. doi: 10.1016/S0140-6736(05)67006-7

137. Martínez-González MÁ, Corella D, Salas-Salvadó J, et al; PREDIMED Study Investigators. Cohort profile: design and meth-ods of the PREDIMED study. *Int J Epidemiol*. 2012;41:377–385. doi: 10.1093/ije/dyq250

138. Guasch-Ferré M, Salas-Salvadó J, Ros E, Estruch R, Corella D, Fitó M, Martínez-González MA; PREDIMED Investigators. The PREDIMED trial, Mediterranean diet and health outcomes: how strong is the evidence? *Nutr Metab Cardiovasc Dis*. 2017;27:624–632. doi: 10.1016/j.numecd.2017.05.004

139. Carlisle JB. Data fabrication and other reasons for non-random sampling in 5087 randomised, controlled trials in anaesthetic and general medical journals. *Anaesthesia*. 2017;72:944–952. doi: 10.1111/anae.13938

140. Ioannidis JA. The challenge of reforming nutritional epidemiologic research. Viewpoint. *JAMA*. 2018;320:969–970.

141. Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi A, Helsing E, Trichopoulos D. Mediterranean diet pyramid: a cultural model for healthy eating. *Am J Clin Nutr*. 1995;61:1402S–1406S. doi: 10.1093/ajcn/61.6.1402S

142. Keys A. *Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease*. Cambridge, MA: Harvard University Press; 1980.

143. Tracy SW. Something new under the sun? The Mediterranean diet and cardiovascular health. *N Engl J Med*. 2013;368:1274–1276. doi: 10.1056/NEJMp1302616

144. Neuhouser ML. The importance of healthy dietary patterns in chronic disease prevention [published online July 10, 2018]. *Nutr Res*. doi: 10.1016/j.nutres.2018.06.002. https://www.sciencedirect.com/science/article/pii/S0271531718302227?via%3Dihub.

145. Bach-Faig A, Berry EM, Lairon D, Reguant J, Trichopoulou A, Dernini S, Medina FX, Battino M, Belahsen R, Miranda G, Serra-Majem L; Mediterranean Diet Foundation Expert Group. Mediterranean diet pyramid today. Science and cultural updates. *Public Health Nutr*. 2011;14:2274–2284. doi: 10.1017/S1368980011002515

146. Millen BE, Abrams S, Adams-Campbell L, Anderson CA, Brenna JT, Campbell WW, Clinton S, Hu F, Nelson M, Neuhouser ML, Perez-Escamilla R, Siega-Riz AM, Story M, Lichtenstein AH. The 2015 dietary guidelines advisory committee scientific report: development and major conclusions. *Adv Nutr*. 2016;7:438–444. doi: 10.3945/an.116.012120

147. Zaragoza-Martí A, Cabañero-Martínez MJ, Hurtado-Sánchez JA, Laguna-Pérez A, Ferrer-Cascales R. Evaluation of Mediterranean diet adherence scores: a systematic review. *BMJ Open*. 2018;8:e019033. doi: 10.1136/bmjopen-2017–019033.

148. Mukamal K, Lazo M. Alcohol and cardiovascular disease. *BMJ*. 2017;356:j1340. doi: 10.1136/bmj.j1340

149. Gea A, Bes-Rastrollo M, Toledo E, Garcia-Lopez M, Beunza JJ, Estruch R, Martinez-Gonzalez MA. Mediterranean alcohol-drinking pat-tern and mortality in the SUN (Seguimiento Universidad de Navarra) Project: a prospective cohort study. *Br J Nutr*. 2014;111:1871–1880. doi: 10.1017/S0007114513004376

150. Kloner RA, Rezkalla SH. To drink or not to drink? That is the question. *Circulation*. 2007;116:1306–1317. doi: 10.1161/CIRCULATIONAHA.106.678375

151. Rimm EB, Ellison RC. Alcohol in the Mediterranean diet. *Am J Clin Nutr*. 1995;61:1378S–1382S. doi: 10.1093/ajcn/61.6.1378S

152. Hill AB. The environment and disease: association or causation? *Proc R Soc Med*. 1965;58:295–300.

153. Panagiotakos DB, Georgousopoulou EN, Pitsavos C, Chrysohoou C, Metaxa V, Georgiopoulos GA, Kalogeropoulou K, Tousoulis D, Stefanadis C; ATTICA Study Group. Ten-year (2002-2012) cardio-vascular disease incidence and all-cause mortality, in urban Greek

population: the ATTICA Study. *Int J Cardiol*. 2015;180:178–184. doi: 10.1016/j.ijcard.2014.11.206

154. Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. *J Am Coll Cardiol*. 2011;57:1299–1313. doi: 10.1016/j.jacc.2010.09.073

155. Ruiz-Canela M, Estruch R, Corella D, Salas-Salvadó J, Martínez-González MA. Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial. *JAMA*. 2014;311:415–417. doi: 10.1001/jama.2013.280618

156. Drewnowski A. Concept of a nutritious food: toward a nutrient density score. *Am J Clin Nutr*. 2005;82:721–732. doi: 10.1093/ajcn/82.4.721

157. Maillot M, Issa C, Vieux F, Lairon D, Darmon N. The shortest way to reach nutritional goals is to adopt Mediterranean food choices: evidence from computer-generated personalized diets. *Am J Clin Nutr*. 2011;94:1127–1137. doi: 10.3945/ajcn.111.016501

158. Román-Viñas B, Ribas Barba L, Ngo J, Martínez-González MA, Wijnhoven TM, Serra-Majem L. Validity of dietary patterns to assess nutrient intake adequacy in a Mediterranean cohort: the SUN (Seguimiento Universidad de Navarra) Project. *Br J Nutr*. 2009;101(suppl 2):S12–S20. doi: 10.1017/S0007114509990547

159. Zazpe I, Sánchez-Taínta A, Santiago S, de la Fuente-Arrillaga C, Bes-Rastrollo M, Martínez JA, Martínez-González MÁ; SUN Project Investigators. Association between dietary carbohydrate intake quality and micronutrient intake adequacy in a Mediterranean cohort: the SUN (Seguimiento Universidad de Navarra) Project. *Br J Nutr*. 2014;111:2000–2009. doi: 10.1017/S0007114513004364

160. Castro-Quezada I, Román-Viñas B, Serra-Majem L. The Mediterranean diet and nutritional adequacy: a review. *Nutrients*. 2014;6:231–248. doi: 10.3390/nu6010231

161. Sánchez-Tainta A, Zazpe I, Bes-Rastrollo M, et al; PREDIMED Study Investigators. Nutritional adequacy according to carbohydrates and fat quality. *Eur J Nutr*. 2016;55:93–106. doi: 10.1007/s00394-014-0828-3

162. Chiuve SE, Sampson L, Willett WC. The association between a nutritional quality index and risk of chronic disease. *Am J Prev Med*. 2011;40:505–513. doi: 10.1016/j.amepre.2010.11.022

163. Lupoli R, Vaccaro A, Ambrosino P, Poggio P, Amato M, Di Minno MN. Impact of Vitamin D deficiency on subclinical carotid atherosclerosis: a pooled analysis of cohort studies [published online May 9, 2017]. *J Clin Endocrinol Metab*. doi: 10.1210/jc.2017-00342. https://academic.oup.com/jcem/article/102/7/2146/3805503.

164. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. *Ann Intern Med*. 2017;167:268–274. doi: 10.7326/M16-2607

165. Tresserra-Rimbau A, Rimm EB, Medina-Remón A, et al; PREDIMED Study Investigators. Inverse association between habitual polyphenol intake and incidence of cardiovascular events in the PREDIMED study. *Nutr Metab Cardiovasc Dis*. 2014;24:639–647. doi: 10.1016/j.numecd.2013.12.014

166. Medina-Remón A, Zamora-Ros R, Rotchés-Ribalta M, et al; PREDIMED Study Investigators. Total polyphenol excretion and blood pressure in subjects at high cardiovascular risk. *Nutr Metab Cardiovasc Dis*. 2011;21:323–331. doi: 10.1016/j.numecd.2009.10.019

167. Tresserra-Rimbau A, Rimm EB, Medina-Remón A, et al; PREDIMED Study Investigators. Polyphenol intake and mortality risk: a re-analysis of the PREDIMED trial. *BMC Med*. 2014;12:77. doi: 10.1186/1741-7015-12-77

168. Llorente-Cortés V, Estruch R, Mena MP, Ros E, González MA, Fitó M, Lamuela-Raventós RM, Badimon L. Effect of Mediterranean diet on the expression of pro-atherogenic genes in a population at high cardiovascular risk. *Atherosclerosis*. 2010;208:442–450. doi: 10.1016/j.atherosclerosis.2009.08.004

169. Ruiz-Canela M, Toledo E, Clish CB, et al. Plasma branched-chain amino acids and incident cardiovascular disease in the PREDIMED Trial. *Clin Chem*. 2016;62:582–592. doi: 10.1373/clinchem.2015.251710

170. Wang DD, Toledo E, Hruby A, et al. Plasma ceramides, Mediterranean diet, and incident cardiovascular disease in the PREDIMED Trial (Prevención con Dieta Mediterránea). *Circulation*. 2017;135:2028–2040. doi: 10.1161/CIRCULATIONAHA.116.024261

171. Yu E, Ruiz-Canela M, Guasch-Ferré M, et al. Increases in plasma tryptophan are inversely associated with incident cardiovascular disease in the prevención con dieta mediterránea (PREDIMED) study. *J Nutr*. 2017;147:314–322. doi: 10.3945/jn.116.241711

172. Scoditti E, Calabriso N, Massaro M, Pellegrino M, Storelli C, Martines G, De Caterina R, Carluccio MA. Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. *Arch Biochem Biophys*. 2012;527:81–89. doi: 10.1016/j.abb.2012.05.003

173. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ*. 2011;342:d549. doi: 10.1136/bmj.d549